DE69032425D1 - Teststreifen zum Eintauchen für Nukleinsäure-Hybridisierungsassays und Verfahren zur kovalenten Immobilisierung von Oligonucleotiden - Google Patents

Teststreifen zum Eintauchen für Nukleinsäure-Hybridisierungsassays und Verfahren zur kovalenten Immobilisierung von Oligonucleotiden

Info

Publication number: DE69032425D1
Authority: DE; Germany
Prior art keywords: nucleic acid; acid hybridization; methods; test strips; hybridization assays
Prior art date: 1990-05-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69032425T

Other languages

English (en)

Other versions

DE69032425T2 (de

Inventor

Ness Jeffrey Van

John C Tabone

Charles E Petrie

Nicolaas M J Vermeulen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Nanogen Inc

Original Assignee

MicroProbe Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-05-11

Filing date

1990-09-04

Publication date

1998-07-23

1990-09-04 Application filed by MicroProbe Corp filed Critical MicroProbe Corp

1998-07-23 Application granted granted Critical

1998-07-23 Publication of DE69032425D1 publication Critical patent/DE69032425D1/de

1998-11-26 Publication of DE69032425T2 publication Critical patent/DE69032425T2/de

2010-09-05 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 3
238000003556 assay Methods 0.000 title abstract 2
238000007899 nucleic acid hybridization Methods 0.000 title abstract 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
238000007654 immersion Methods 0.000 title 1
230000003100 immobilizing effect Effects 0.000 title 1
238000000034 method Methods 0.000 title 1
239000011324 bead Substances 0.000 abstract 5
229920000642 polymer Polymers 0.000 abstract 4
108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
239000004677 Nylon Substances 0.000 abstract 1
150000007523 nucleic acids Chemical group 0.000 abstract 1
229920001778 nylon Polymers 0.000 abstract 1
239000007787 solid Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Biochemistry (AREA)
Analytical Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Zoology (AREA)
Physics & Mathematics (AREA)
Hematology (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Cell Biology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Food Science & Technology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Apparatus Associated With Microorganisms And Enzymes (AREA)
Saccharide Compounds (AREA)

DE69032425T 1990-05-11 1990-09-04 Teststreifen zum Eintauchen für Nukleinsäure-Hybridisierungsassays und Verfahren zur kovalenten Immobilisierung von Oligonucleotiden Expired - Lifetime DE69032425T2 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US52244290A	1990-05-11	1990-05-11

Publications (2)

Publication Number	Publication Date
DE69032425D1 true DE69032425D1 (de)	1998-07-23
DE69032425T2 DE69032425T2 (de)	1998-11-26

Family

ID=24080872

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69032425T Expired - Lifetime DE69032425T2 (de)	1990-05-11	1990-09-04	Teststreifen zum Eintauchen für Nukleinsäure-Hybridisierungsassays und Verfahren zur kovalenten Immobilisierung von Oligonucleotiden

Country Status (7)

Country	Link
US (1)	US5514785A (de)
EP (2)	EP0455905B1 (de)
JP (1)	JPH0420300A (de)
AT (1)	ATE167523T1 (de)
DE (1)	DE69032425T2 (de)
DK (1)	DK0455905T3 (de)
ES (1)	ES2116977T3 (de)

Families Citing this family (1023)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6040138A (en)	1995-09-15	2000-03-21	Affymetrix, Inc.	Expression monitoring by hybridization to high density oligonucleotide arrays
WO1992010588A1 (en) *	1990-12-06	1992-06-25	Affymax Technologies N.V.	Sequencing by hybridization of a target nucleic acid to a matrix of defined oligonucleotides
US6335434B1 (en)	1998-06-16	2002-01-01	Isis Pharmaceuticals, Inc.,	Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en)	1991-11-19	2012-04-10	Isis Pharmaceuticals, Inc.	Composition and methods for the pulmonary delivery of nucleic acids
US5747244A (en) *	1991-12-23	1998-05-05	Chiron Corporation	Nucleic acid probes immobilized on polystyrene surfaces
CA2126748A1 (en) *	1991-12-24	1993-06-25	Tepnel Medical Limited	Manipulating nucleic acid sequences
US6436635B1 (en)	1992-11-06	2002-08-20	Boston University	Solid phase sequencing of double-stranded nucleic acids
US5795714A (en)	1992-11-06	1998-08-18	Trustees Of Boston University	Method for replicating an array of nucleic acid probes
US6207651B1 (en) *	1996-08-02	2001-03-27	Metabolite Laboratories	Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6
AU675251B2 (en) *	1993-01-04	1997-01-30	Becton Dickinson & Company	Flow-through hybridization assay for oligonucleotide sequences
US6194144B1 (en)	1993-01-07	2001-02-27	Sequenom, Inc.	DNA sequencing by mass spectrometry
US5679510A (en) *	1993-04-27	1997-10-21	Hybridon, Inc.	Quantitative detection of specific nucleic acid sequences using lambdoid bacteriophages linked by oligonucleotides to solid support
CA2170869C (en)	1993-09-03	1999-09-14	Phillip Dan Cook	Amine-derivatized nucleosides and oligonucleosides
DE4409436A1 (de) *	1994-03-19	1995-09-21	Boehringer Mannheim Gmbh	Verfahren zur Bearbeitung von Nukleinsäuren
AU707391B2 (en) *	1994-05-28	1999-07-08	Tepnel Medical Limited	Producing copies of nucleic acids
US7323298B1 (en) *	1994-06-17	2008-01-29	The Board Of Trustees Of The Leland Stanford Junior University	Microarray for determining the relative abundances of polynuceotide sequences
US7378236B1 (en)	1994-06-17	2008-05-27	The Board Of Trustees Of The Leland Stanford Junior University	Method for analyzing gene expression patterns
US5807522A (en) *	1994-06-17	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods for fabricating microarrays of biological samples
US5578446A (en) *	1994-07-08	1996-11-26	Becton Dickinson And Company	Analytical dipstick for improved mixing and reduced reagent volume
US8236493B2 (en) *	1994-10-21	2012-08-07	Affymetrix, Inc.	Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA
US6428955B1 (en)	1995-03-17	2002-08-06	Sequenom, Inc.	DNA diagnostics based on mass spectrometry
US7803529B1 (en)	1995-04-11	2010-09-28	Sequenom, Inc.	Solid phase sequencing of biopolymers
US6420549B1 (en)	1995-06-06	2002-07-16	Isis Pharmaceuticals, Inc.	Oligonucleotide analogs having modified dimers
JP3517031B2 (ja) *	1995-06-09	2004-04-05	日清紡績株式会社	生物学的活性物質の分析法
US6291166B1 (en) *	1997-04-16	2001-09-18	Xtrana, Inc.	Nucleic acid archiving
CA2235762A1 (en) *	1995-11-14	1997-05-22	Genometrix Genomics, Inc.	Integrated nucleic acid hybridization devices based upon active surface chemistry
US5854033A (en)	1995-11-21	1998-12-29	Yale University	Rolling circle replication reporter systems
EP0880598A4 (de)	1996-01-23	2005-02-23	Affymetrix Inc	Verfahren zur analyse von nukleinsäure
ES2288760T3 (es)	1996-04-25	2008-01-16	Bioarray Solutions Ltd.	Ensamblaje electrocinetico controlado por luz de particulas proximas a superficies.
US20070275921A1 (en) *	1996-06-06	2007-11-29	Isis Pharmaceuticals, Inc.	Oligomeric Compounds That Facilitate Risc Loading
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US20080119427A1 (en) *	1996-06-06	2008-05-22	Isis Pharmaceuticals, Inc.	Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
US20040266706A1 (en) *	2002-11-05	2004-12-30	Muthiah Manoharan	Cross-linked oligomeric compounds and their use in gene modulation
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US7812149B2 (en)	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20030044941A1 (en)	1996-06-06	2003-03-06	Crooke Stanley T.	Human RNase III and compositions and uses thereof
WO1998004740A1 (en) *	1996-07-29	1998-02-05	Nanosphere Llc	Nanoparticles having oligonucleotides attached thereto and uses therefor
US5900481A (en) *	1996-11-06	1999-05-04	Sequenom, Inc.	Bead linkers for immobilizing nucleic acids to solid supports
US6140053A (en)	1996-11-06	2000-10-31	Sequenom, Inc.	DNA sequencing by mass spectrometry via exonuclease degradation
JP2008298785A (ja) *	1996-11-06	2008-12-11	Sequenom Inc	固体支持体に核酸を固定化するための組成物および方法
US6133436A (en) *	1996-11-06	2000-10-17	Sequenom, Inc.	Beads bound to a solid support and to nucleic acids
ATE204290T1 (de) *	1996-11-06	2001-09-15	Sequenom Inc	Zusammensetzungen und verfahren zur immobilisierung von nukleinsäure auf festträgern
AU2002300406B9 (en) *	1996-11-06	2005-11-03	Sequenom, Inc.	Compositions and Methods for Immobilizing Nucleic Acids to Solid Supports
EP0954612A2 (de)	1996-11-06	1999-11-10	Sequenom, Inc.	Dna-diagnostik mittels massenspektrometrie
EP1460083B1 (de)	1996-11-06	2006-01-18	Sequenom, Inc.	Verfahren zur Analyse und Vorrichtung
WO1999001579A1 (en)	1997-07-01	1999-01-14	Isis Pharmaceuticals, Inc.	Compositions and methods for the delivery of oligonucleotides via the alimentary canal
EP0996500A1 (de)	1997-07-22	2000-05-03	Rapigene, Inc.	Vorrichtung und verfahren zur gruppierung von einer lösung auf einem festen träger
US6268131B1 (en)	1997-12-15	2001-07-31	Sequenom, Inc.	Mass spectrometric methods for sequencing nucleic acids
EP1057001A2 (de) *	1998-02-19	2000-12-06	Edvotek	Hergestellte vorrichtungen und methoden zum färben von biomolekülen
US6013789A (en) *	1998-02-20	2000-01-11	Beckman Coulter, Inc.	Covalent attachment of biomolecules to derivatized polypropylene supports
EP1058832A1 (de)	1998-02-21	2000-12-13	Basf Aktiengesellschaft	Verwendung von fluoreszenzfarbstoffen zur oberflächenuntersuchung
US20040186071A1 (en) *	1998-04-13	2004-09-23	Bennett C. Frank	Antisense modulation of CD40 expression
US7321828B2 (en) *	1998-04-13	2008-01-22	Isis Pharmaceuticals, Inc.	System of components for preparing oligonucleotides
US6048695A (en)	1998-05-04	2000-04-11	Baylor College Of Medicine	Chemically modified nucleic acids and methods for coupling nucleic acids to solid support
US6979728B2 (en) *	1998-05-04	2005-12-27	Baylor College Of Medicine	Articles of manufacture and methods for array based analysis of biological molecules
US6723564B2 (en)	1998-05-07	2004-04-20	Sequenom, Inc.	IR MALDI mass spectrometry of nucleic acids using liquid matrices
US6841539B1 (en)	1998-05-21	2005-01-11	Isis Pharmaceuticals, Inc.	Compositions and methods for topical delivery of oligonucleotides
WO1999060012A1 (en) *	1998-05-21	1999-11-25	Isis Pharmaceuticals, Inc.	Compositions and methods for non-parenteral delivery of oligonucleotides
US6335439B1 (en)	1998-06-11	2002-01-01	Isis Pharmaceuticals, Inc.	Method of preparing phosphoramidites
US6867294B1 (en)	1998-07-14	2005-03-15	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US7640083B2 (en) *	2002-11-22	2009-12-29	Monroe David A	Record and playback system for aircraft
US6225293B1 (en)	1998-09-02	2001-05-01	Isis Pharmaceuticals, Inc.	Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
US6077709A (en)	1998-09-29	2000-06-20	Isis Pharmaceuticals Inc.	Antisense modulation of Survivin expression
US6667176B1 (en)	2000-01-11	2003-12-23	Geron Corporation	cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
BE1012275A3 (fr) *	1998-11-12	2000-08-01	Univ Bruxelles	Fixation covalente d'oligonucleotides a la surface du nylon.
AU764964B2 (en) *	1998-11-23	2003-09-04	Usamriid	Purification method and apparatus
US6638760B1 (en) *	1998-11-25	2003-10-28	Pe Corporation (Ny)	Method and apparatus for flow-through hybridization
US6300320B1 (en)	1999-01-05	2001-10-09	Isis Pharmaceuticals, Inc.	Modulation of c-jun using inhibitors of protein kinase C
US6127124A (en) *	1999-01-20	2000-10-03	Isis Pharmaceuticals, Inc.	Fluorescence based nuclease assay
DE19903576C2 (de)	1999-01-29	2001-02-22	Bodenseewerk Perkin Elmer Co	Quantitative Bestimmung von Analyten in einem heterogenen System
EP1434055B1 (de) *	1999-02-16	2006-09-27	Applera Corporation	Vorrichtung zur Handhabung von Kügelchen
US7098192B2 (en)	1999-04-08	2006-08-29	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of STAT3 expression
US6268141B1 (en) *	1999-05-12	2001-07-31	Beckman Coulter, Inc.	Immobilization of unmodified biopolymers to acyl fluoride activated substrates
US6656730B1 (en)	1999-06-15	2003-12-02	Isis Pharmaceuticals, Inc.	Oligonucleotides conjugated to protein-binding drugs
US6339147B1 (en)	1999-07-29	2002-01-15	Epoch Biosciences, Inc.	Attachment of oligonucleotides to solid supports through Schiff base type linkages for capture and detection of nucleic acids
US6147200A (en) *	1999-08-19	2000-11-14	Isis Pharmaceuticals, Inc.	2'-O-acetamido modified monomers and oligomers
US6617442B1 (en) *	1999-09-30	2003-09-09	Isis Pharmaceuticals, Inc.	Human Rnase H1 and oligonucleotide compositions thereof
US20030190644A1 (en) *	1999-10-13	2003-10-09	Andreas Braun	Methods for generating databases and databases for identifying polymorphic genetic markers
AU2622101A (en) *	1999-11-02	2001-05-14	Celine Hu	Molecular microarrays and methods for production and use thereof
US7109024B2 (en) *	1999-11-15	2006-09-19	Dr. Chip Biotechnology Inc.	Biomolecule-bound substrates
US6261840B1 (en)	2000-01-18	2001-07-17	Isis Pharmaceuticals, Inc.	Antisense modulation of PTP1B expression
US20020055479A1 (en)	2000-01-18	2002-05-09	Cowsert Lex M.	Antisense modulation of PTP1B expression
EP1255603A1 (de) *	2000-02-09	2002-11-13	RESQ Lab B.V.	Packungsmaterial für die trennung von biomolekülen
US20030176385A1 (en) *	2000-02-15	2003-09-18	Jingfang Ju	Antisense modulation of protein expression
US6413722B1 (en) *	2000-03-22	2002-07-02	Incyte Genomics, Inc.	Polymer coated surfaces for microarray applications
US6911535B2 (en) *	2000-03-22	2005-06-28	Solvlink Biosciences	Biomolecule/polymer conjugates
AU5340801A (en) *	2000-04-13	2001-10-30	Thomas N Wight	Therapeutic compounds and methods
US6458589B1 (en)	2000-04-27	2002-10-01	Geron Corporation	Hepatocyte lineage cells derived from pluripotent stem cells
US6680172B1 (en)	2000-05-16	2004-01-20	Regents Of The University Of Michigan	Treatments and markers for cancers of the central nervous system
AU2001255518A1 (en) *	2000-06-07	2001-12-17	Baylor College Of Medicine	Compositions and methods for array-based nucleic acid hybridization
US20060166227A1 (en) *	2000-06-20	2006-07-27	Stephen Kingsmore	Protein expression profiling
US7892854B2 (en)	2000-06-21	2011-02-22	Bioarray Solutions, Ltd.	Multianalyte molecular analysis using application-specific random particle arrays
US9709559B2 (en)	2000-06-21	2017-07-18	Bioarray Solutions, Ltd.	Multianalyte molecular analysis using application-specific random particle arrays
US6323009B1 (en) *	2000-06-28	2001-11-27	Molecular Staging, Inc.	Multiply-primed amplification of nucleic acid sequences
US6958214B2 (en)	2000-07-10	2005-10-25	Sequenom, Inc.	Polymorphic kinase anchor proteins and nucleic acids encoding the same
US8568766B2 (en)	2000-08-24	2013-10-29	Gattadahalli M. Anantharamaiah	Peptides and peptide mimetics to treat pathologies associated with eye disease
AU9684601A (en)	2000-10-12	2002-04-22	Univ Rochester	Compositions that inhibit proliferation of cancer cells
US20030045005A1 (en) *	2000-10-17	2003-03-06	Michael Seul	Light-controlled electrokinetic assembly of particles near surfaces
US7767802B2 (en)	2001-01-09	2010-08-03	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of anti-apoptotic genes
WO2002061146A1 (en) *	2001-02-01	2002-08-08	The Trustees Of Columbia University In The City Of New York	Use of electrical fields to control interactions between proteins and nucleic acid constructions immobilized on solid supports
WO2002072790A2 (en)	2001-03-14	2002-09-19	Myriad Genetics, Inc	Tsg101-gag interaction and use thereof
US7803915B2 (en) *	2001-06-20	2010-09-28	Genentech, Inc.	Antibody compositions for the diagnosis and treatment of tumor
US20050107595A1 (en) *	2001-06-20	2005-05-19	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
KR100576674B1 (ko)	2001-06-20	2006-05-10	제넨테크, 인크.	종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
AU2002315393A1 (en)	2001-06-21	2003-01-08	Isis Pharmaceuticals, Inc.	Antisense modulation of superoxide dismutase 1, soluble expression
US7262063B2 (en)	2001-06-21	2007-08-28	Bio Array Solutions, Ltd.	Directed assembly of functional heterostructures
WO2003006676A2 (en)	2001-07-13	2003-01-23	Nanosphere, Inc.	Method for immobilizing molecules onto surfaces
US7297553B2 (en) *	2002-05-28	2007-11-20	Nanosphere, Inc.	Method for attachment of silylated molecules to glass surfaces
WO2005108625A2 (en)	2001-07-13	2005-11-17	Nanosphere, Inc.	Method for preparing substrates having immobilized molecules and substrates
US6964950B2 (en)	2001-07-25	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of C-reactive protein expression
US7425545B2 (en)	2001-07-25	2008-09-16	Isis Pharmaceuticals, Inc.	Modulation of C-reactive protein expression
US20030096772A1 (en)	2001-07-30	2003-05-22	Crooke Rosanne M.	Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US7227014B2 (en)	2001-08-07	2007-06-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
ES2431929T3 (es)	2001-09-18	2013-11-28	Genentech, Inc.	Composiciones y procedimientos para el diagnóstico y el tratamiento de tumores
US7195913B2 (en)	2001-10-05	2007-03-27	Surmodics, Inc.	Randomly ordered arrays and methods of making and using
EP1434571B1 (de)	2001-10-05	2005-05-11	SurModics, Inc.	Beschichtungen mit immobilisierten partikeln sowie verwendungen derselben
US6750019B2 (en)	2001-10-09	2004-06-15	Isis Pharmaceuticals, Inc.	Antisense modulation of insulin-like growth factor binding protein 5 expression
EP2270231A3 (de)	2001-10-09	2011-04-27	ISIS Pharmaceuticals, Inc.	Antisense Modulation der Expression von insulin-like growth factor binding protein 5
EP1451318A4 (de) *	2001-10-12	2007-06-27	Perkinelmer Las Inc	Zusammenstellungen von nukleinsäuren und arrays und verfahren zu ihrer verwendung
US7439346B2 (en) *	2001-10-12	2008-10-21	Perkinelmer Las Inc.	Nucleic acids arrays and methods of use therefor
CA2497740C (en)	2001-10-15	2011-06-21	Bioarray Solutions, Ltd.	Multiplexed analysis of polymorphic loci by probe elongation-mediated detection
AU2002364945A1 (en) *	2001-10-25	2003-07-09	Neurogenetics, Inc.	Genes and polymorphisms on chromosome 10 associated with alzheimer's disease and other neurodegenerative diseases
US20030170678A1 (en) *	2001-10-25	2003-09-11	Neurogenetics, Inc.	Genetic markers for Alzheimer's disease and methods using the same
US20030224380A1 (en) *	2001-10-25	2003-12-04	The General Hospital Corporation	Genes and polymorphisms on chromosome 10 associated with Alzheimer's disease and other neurodegenerative diseases
DE10154291B4 (de) *	2001-11-05	2005-05-19	Hain Lifescience Gmbh	Verfahren zum Nachweis von Nukleinsäuren in Form eines Trockenschnelltestes
US20030124599A1 (en) *	2001-11-14	2003-07-03	Shiping Chen	Biochemical analysis system with combinatorial chemistry applications
US6927029B2 (en)	2001-12-03	2005-08-09	Agilent Technologies, Inc.	Surface with tethered polymeric species for binding biomolecules
US6965025B2 (en)	2001-12-10	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of connective tissue growth factor expression
US20030119203A1 (en)	2001-12-24	2003-06-26	Kimberly-Clark Worldwide, Inc.	Lateral flow assay devices and methods for conducting assays
US8367013B2 (en) *	2001-12-24	2013-02-05	Kimberly-Clark Worldwide, Inc.	Reading device, method, and system for conducting lateral flow assays
JP3634307B2 (ja) *	2001-12-27	2005-03-30	三菱電機株式会社	チャット管理システム
US20030124542A1 (en) *	2001-12-28	2003-07-03	Spectral Genomics, Inc.	Methods for mapping the chromosomal loci of genes expressed by a cell
EP2067472A1 (de)	2002-01-02	2009-06-10	Genentech, Inc.	Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
US7122314B2 (en) *	2002-01-30	2006-10-17	Id Biomedical Corporation	Methods for detecting vancomycin-resistant microorganisms and compositions therefor
CA2474530A1 (en) *	2002-02-07	2003-08-14	Eastern Virginia Medical School Of The Medical College Of Hampton Roads	Diagnostic microarray and method of use thereof
US7553619B2 (en) *	2002-02-08	2009-06-30	Qiagen Gmbh	Detection method using dissociated rolling circle amplification
WO2003080649A2 (en) *	2002-03-20	2003-10-02	Regents Of The University Of Minnesota	Induction of hepatocyte proliferation in vitro by inhibition of cell cycle inhibitors
US20030180712A1 (en)	2002-03-20	2003-09-25	Biostratum Ab	Inhibition of the beta3 subunit of L-type Ca2+ channels
US7169916B2 (en) *	2002-04-01	2007-01-30	Isis Pharmaceuticals, Inc.	Chloral-free DCA in oligonucleotide synthesis
CA2481507A1 (en)	2002-04-16	2003-10-30	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US7432342B2 (en) *	2002-05-03	2008-10-07	Sequenom, Inc.	Kinase anchor protein muteins, peptides thereof and related documents
US7199107B2 (en)	2002-05-23	2007-04-03	Isis Pharmaceuticals, Inc.	Antisense modulation of kinesin-like 1 expression
US20040092470A1 (en) *	2002-06-18	2004-05-13	Leonard Sherry A.	Dry powder oligonucleotide formualtion, preparation and its uses
JP2004097173A (ja) *	2002-07-17	2004-04-02	Toyo Kohan Co Ltd	静電層を有する固体支持体及びその用途
US20040019000A1 (en) *	2002-07-19	2004-01-29	Muthiah Manoharan	Polyalkyleneamine-containing oligomers
EP2116604A1 (de)	2002-08-05	2009-11-11	University of Rochester	Proteinumwandlungsdomäne / Deaminasechimäre Proteine, zugehörige Verbindungen und Verwendungen davon
US6878805B2 (en) *	2002-08-16	2005-04-12	Isis Pharmaceuticals, Inc.	Peptide-conjugated oligomeric compounds
US7923260B2 (en)	2002-08-20	2011-04-12	Illumina, Inc.	Method of reading encoded particles
EP1535241A1 (de) *	2002-08-20	2005-06-01	Cyvera Corporation	Auf einem beugungsgitter basierendes optisches identifikationselement
US7900836B2 (en)	2002-08-20	2011-03-08	Illumina, Inc.	Optical reader system for substrates having an optically readable code
US7901630B2 (en)	2002-08-20	2011-03-08	Illumina, Inc.	Diffraction grating-based encoded microparticle assay stick
JP4485949B2 (ja) *	2002-08-20	2010-06-23	シヴェラコーポレイション	マルチプレックス実験用の回折格子ベースのコード化マイクロパーティクル
US7619819B2 (en)	2002-08-20	2009-11-17	Illumina, Inc.	Method and apparatus for drug product tracking using encoded optical identification elements
US7441703B2 (en)	2002-08-20	2008-10-28	Illumina, Inc.	Optical reader for diffraction grating-based encoded optical identification elements
US7872804B2 (en)	2002-08-20	2011-01-18	Illumina, Inc.	Encoded particle having a grating with variations in the refractive index
US7164533B2 (en)	2003-01-22	2007-01-16	Cyvera Corporation	Hybrid random bead/chip based microarray
US7508608B2 (en)	2004-11-17	2009-03-24	Illumina, Inc.	Lithographically fabricated holographic optical identification element
US7285424B2 (en)	2002-08-27	2007-10-23	Kimberly-Clark Worldwide, Inc.	Membrane-based assay devices
US7314763B2 (en) *	2002-08-27	2008-01-01	Kimberly-Clark Worldwide, Inc.	Fluidics-based assay devices
US7432105B2 (en)	2002-08-27	2008-10-07	Kimberly-Clark Worldwide, Inc.	Self-calibration system for a magnetic binding assay
AU2003270655A1 (en) *	2002-09-12	2004-04-30	Cyvera Corporation	Assay stick comprising coded microbeads
US7092160B2 (en)	2002-09-12	2006-08-15	Illumina, Inc.	Method of manufacturing of diffraction grating-based optical identification element
US20100255603A9 (en)	2002-09-12	2010-10-07	Putnam Martin A	Method and apparatus for aligning microbeads in order to interrogate the same
CA2499037A1 (en) *	2002-09-12	2004-03-25	Cyvera Corporation	Method and apparatus for labelling using diffraction grating-based encoded optical identification elements
AU2003267192A1 (en) *	2002-09-12	2004-04-30	Cyvera Corporation	Method and apparatus for aligning elongated microbeads in order to interrogate the same
AU2003274979A1 (en) *	2002-09-12	2004-04-30	Cyvera Corporation	Chemical synthesis using diffraction grating-based encoded optical elements
EP1540591A1 (de) *	2002-09-12	2005-06-15	Cyvera Corporation	Mit hilfe eines beugungsgitters kodierte mikropartikeln für multiplex-experimente
JP2005538186A (ja)	2002-09-13	2005-12-15	レプリコールインコーポレーティッド	非配列相補性の抗ウイルス性オリゴヌクレオチド
CA2498320A1 (en) *	2002-09-20	2004-04-01	Integrated Dna Technologies, Inc.	Anthraquinone quencher dyes, their methods of preparation and use
JP2006500030A (ja)	2002-09-20	2006-01-05	イェールユニバーシティ	リボスイッチ、その使用方法、ならびにリボスイッチとともに用いるための組成物
AU2003278957A1 (en)	2002-09-26	2004-04-23	Amgen, Inc.	Modulation of forkhead box o1a expression
JP2006515318A (ja) *	2002-10-29	2006-05-25	ファルマシア・コーポレーション	特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法
WO2004043979A2 (en)	2002-11-05	2004-05-27	Isis Pharmaceuticals, Inc.	Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
CA2504720C (en)	2002-11-05	2013-12-24	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
WO2004041889A2 (en)	2002-11-05	2004-05-21	Isis Pharmaceuticals, Inc.	Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US9150606B2 (en) *	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US9150605B2 (en) *	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
ES2417879T3 (es)	2002-11-13	2013-08-09	Genzyme Corporation	Modulación antisentido de la expresión de la apolipoproteína B
EP2336318B1 (de)	2002-11-13	2013-04-24	Genzyme Corporation	Antisense-modulation von apolipoprotein-b-expression
WO2004047007A1 (en)	2002-11-15	2004-06-03	Bioarray Solutions, Ltd.	Analysis, secure access to, and transmission of array images
US7754450B2 (en)	2002-11-15	2010-07-13	Morphotek, Inc.	Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
CN100594037C (zh)	2002-11-15	2010-03-17	Musc研究发展基金会	通过补体受体2定向的补体调节剂
AU2003294462C1 (en)	2002-11-21	2011-06-30	University Of Utah Research Foundation	Purinergic modulation of smell
US7144999B2 (en)	2002-11-23	2006-12-05	Isis Pharmaceuticals, Inc.	Modulation of hypoxia-inducible factor 1 alpha expression
US20040121334A1 (en) *	2002-12-19	2004-06-24	Kimberly-Clark Worldwide, Inc.	Self-calibrated flow-through assay devices
US20040121339A1 (en) *	2002-12-19	2004-06-24	Jizhong Zhou	Special film-coated substrate for bio-microarray fabrication and use thereof
US7247500B2 (en) *	2002-12-19	2007-07-24	Kimberly-Clark Worldwide, Inc.	Reduction of the hook effect in membrane-based assay devices
JP4886298B2 (ja)	2002-12-20	2012-02-29	キアゲンゲゼルシャフトミットベシュレンクテルハフツング	核酸増幅
US9487823B2 (en)	2002-12-20	2016-11-08	Qiagen Gmbh	Nucleic acid amplification
US6977153B2 (en) *	2002-12-31	2005-12-20	Qiagen Gmbh	Rolling circle amplification of RNA
US7468356B2 (en)	2003-02-11	2008-12-23	Antisense Therapeutics Ltd.	Modulation of insulin like growth factor I receptor expression
US7002006B2 (en) *	2003-02-12	2006-02-21	Isis Pharmaceuticals, Inc.	Protection of nucleosides
US7803781B2 (en)	2003-02-28	2010-09-28	Isis Pharmaceuticals, Inc.	Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20070141570A1 (en) *	2003-03-07	2007-06-21	Sequenom, Inc.	Association of polymorphic kinase anchor proteins with cardiac phenotypes and related methods
US20040185559A1 (en)	2003-03-21	2004-09-23	Isis Pharmaceuticals Inc.	Modulation of diacylglycerol acyltransferase 1 expression
US8043834B2 (en)	2003-03-31	2011-10-25	Qiagen Gmbh	Universal reagents for rolling circle amplification and methods of use
US7851209B2 (en) *	2003-04-03	2010-12-14	Kimberly-Clark Worldwide, Inc.	Reduction of the hook effect in assay devices
US20040197819A1 (en) *	2003-04-03	2004-10-07	Kimberly-Clark Worldwide, Inc.	Assay devices that utilize hollow particles
US7598227B2 (en)	2003-04-16	2009-10-06	Isis Pharmaceuticals Inc.	Modulation of apolipoprotein C-III expression
US7399853B2 (en)	2003-04-28	2008-07-15	Isis Pharmaceuticals	Modulation of glucagon receptor expression
US7276599B2 (en) *	2003-06-02	2007-10-02	Isis Pharmaceuticals, Inc.	Oligonucleotide synthesis with alternative solvents
CN1984921B (zh)	2003-06-03	2010-06-16	Isis药物公司	存活蛋白表达的调节
WO2005014782A2 (en)	2003-06-13	2005-02-17	Alnylam Europe Ag.,	Double-stranded ribonucleic acid with increased effectiveness in an organism
WO2004113496A2 (en) *	2003-06-20	2004-12-29	Isis Pharmaceuticals, Inc.	Double stranded compositions comprising a 3’-endo modified strand for use in gene modulation
EP2530157B1 (de)	2003-07-31	2016-09-28	Regulus Therapeutics Inc.	Oligomerverbindungen und Zusammensetzungen zur Verwendung bei der Modulation von miRNAs
US7825235B2 (en)	2003-08-18	2010-11-02	Isis Pharmaceuticals, Inc.	Modulation of diacylglycerol acyltransferase 2 expression
US20050053981A1 (en) *	2003-09-09	2005-03-10	Swayze Eric E.	Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US20070123480A1 (en) *	2003-09-11	2007-05-31	Replicor Inc.	Oligonucleotides targeting prion diseases
SG146682A1 (en)	2003-09-18	2008-10-30	Isis Pharmaceuticals Inc	Modulation of eif4e expression
US7927796B2 (en)	2003-09-18	2011-04-19	Bioarray Solutions, Ltd.	Number coding for identification of subtypes of coded types of solid phase carriers
JP5379347B2 (ja) *	2003-09-18	2013-12-25	アイシスファーマシューティカルズ，インコーポレーテッド	４’−チオヌクレオシドおよびオリゴマー化合物
JP4564959B2 (ja)	2003-09-22	2010-10-20	バイオアレイソリューションズリミテッド	生体分子に共有結合できる、複数の官能基を持つ表面固定化高分子電解質
US7662929B2 (en)	2003-10-10	2010-02-16	Alchemia Oncology Pty Limited	Antibody that specifically binds hyaluronan synthase
US7563569B2 (en)	2003-10-28	2009-07-21	Michael Seul	Optimization of gene expression analysis using immobilized capture probes
AU2004287069B2 (en)	2003-10-29	2009-07-16	Bioarray Solutions, Ltd.	Multiplexed nucleic acid analysis by fragmentation of double-stranded DNA
US20050191653A1 (en)	2003-11-03	2005-09-01	Freier Susan M.	Modulation of SGLT2 expression
WO2005049849A2 (en)	2003-11-14	2005-06-02	Integrated Dna Technologies, Inc.	Fluorescence quenching azo dyes, their methods of preparation and use
PL2295073T3 (pl)	2003-11-17	2014-09-30	Genentech Inc	Przeciwciało przeciwko CD22 do leczenia nowotworu pochodzącego z układu krwiotwórczego
US7713748B2 (en) *	2003-11-21	2010-05-11	Kimberly-Clark Worldwide, Inc.	Method of reducing the sensitivity of assay devices
US20050112703A1 (en) *	2003-11-21	2005-05-26	Kimberly-Clark Worldwide, Inc.	Membrane-based lateral flow assay devices that utilize phosphorescent detection
US7943395B2 (en) *	2003-11-21	2011-05-17	Kimberly-Clark Worldwide, Inc.	Extension of the dynamic detection range of assay devices
US20050136550A1 (en) *	2003-12-19	2005-06-23	Kimberly-Clark Worldwide, Inc.	Flow control of electrochemical-based assay devices
US7943089B2 (en) *	2003-12-19	2011-05-17	Kimberly-Clark Worldwide, Inc.	Laminated assay devices
US20050136500A1 (en) *	2003-12-19	2005-06-23	Kimberly-Clark Worldwide; Inc.	Flow-through assay devices
WO2005071080A2 (en)	2004-01-20	2005-08-04	Isis Pharmaceuticals, Inc.	Modulation of glucocorticoid receptor expression
US8778900B2 (en) *	2004-01-22	2014-07-15	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP1 expression
US7468431B2 (en)	2004-01-22	2008-12-23	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP2 expression
US7433123B2 (en)	2004-02-19	2008-10-07	Illumina, Inc.	Optical identification element having non-waveguide photosensitive substrate with diffraction grating therein
US20050191704A1 (en) *	2004-03-01	2005-09-01	Kimberly-Clark Worldwide, Inc.	Assay devices utilizing chemichromic dyes
US8569474B2 (en)	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8790919B2 (en)	2004-03-15	2014-07-29	Isis Pharmaceuticals, Inc.	Compositions and methods for optimizing cleavage of RNA by RNase H
JP2007531794A (ja)	2004-04-05	2007-11-08	アルニラムファーマスーティカルズインコーポレイテッド	オリゴヌクレオチドの合成および精製に使用する方法および反応試薬
US20050244869A1 (en) *	2004-04-05	2005-11-03	Brown-Driver Vickie L	Modulation of transthyretin expression
US20050260755A1 (en) *	2004-04-06	2005-11-24	Isis Pharmaceuticals, Inc.	Sequential delivery of oligomeric compounds
US20050260652A1 (en) *	2004-04-15	2005-11-24	The General Hospital Corporation	Compositions and methods that modulate RNA interference
CA2562151C (en)	2004-04-30	2016-09-06	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising a c5-modified pyrimidine
DK1773872T3 (en)	2004-05-21	2017-05-08	Uab Res Found	VARIABLE Lymphocyte Receptors, Associated Polypeptides and Nucleic Acids, and Uses thereof
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
CA2569036A1 (en) *	2004-06-03	2005-12-22	Balkrishen Bhat	Chimeric gapped oligomeric compositions
US7094528B2 (en) *	2004-06-30	2006-08-22	Kimberly-Clark Worldwide, Inc.	Magnetic enzyme detection techniques
US7521226B2 (en)	2004-06-30	2009-04-21	Kimberly-Clark Worldwide, Inc.	One-step enzymatic and amine detection technique
US7906276B2 (en)	2004-06-30	2011-03-15	Kimberly-Clark Worldwide, Inc.	Enzymatic detection techniques
US7848889B2 (en)	2004-08-02	2010-12-07	Bioarray Solutions, Ltd.	Automated analysis of multiplexed probe-target interaction patterns: pattern matching and allele identification
US7427675B2 (en) *	2004-08-23	2008-09-23	Isis Pharmaceuticals, Inc.	Compounds and methods for the characterization of oligonucleotides
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
WO2006032143A1 (en)	2004-09-23	2006-03-30	Arc Pharmaceuticals, Inc.	Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
NZ554277A (en)	2004-10-20	2010-09-30	Antisense Therapeutics Ltd	Antisense modulation of integrin alpha 4 expression
EP1869615B1 (de)	2004-11-16	2010-03-03	Illumina, Inc.	Verfahren und vorrichtung zum lesen von kodierten mikrokugeln
US7604173B2 (en)	2004-11-16	2009-10-20	Illumina, Inc.	Holographically encoded elements for microarray and other tagging labeling applications, and method and apparatus for making and reading the same
WO2006055735A2 (en)	2004-11-16	2006-05-26	Illumina, Inc	Scanner having spatial light modulator
WO2006063031A2 (en)	2004-12-06	2006-06-15	Haplomics	Allelic variants of human factor viii
EP1869076A2 (de)	2005-03-10	2007-12-26	Genentech, Inc.	Verfahren und zusammensetzungen zur modulation der gefässintegrität
US7476733B2 (en) *	2005-03-25	2009-01-13	The United States Of America As Represented By The Department Of Health And Human Services	Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
US8309303B2 (en)	2005-04-01	2012-11-13	Qiagen Gmbh	Reverse transcription and amplification of RNA with simultaneous degradation of DNA
US20060281076A1 (en) *	2005-05-18	2006-12-14	Nanosphere, Inc.	Substrate functionalization method for high sensitivity applications
CA2601554A1 (en) *	2005-05-20	2006-11-30	Integrated Dna Technologies, Inc.	Compounds and methods for labeling oligonucleotides
JP5329949B2 (ja)	2005-05-31	2013-10-30	エコーレポリテクニークフェデラーレデローザンヌ	遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
US8486629B2 (en)	2005-06-01	2013-07-16	Bioarray Solutions, Ltd.	Creation of functionalized microparticle libraries by oligonucleotide ligation or elongation
WO2006133022A2 (en)	2005-06-03	2006-12-14	The Johns Hopkins University	Compositions and methods for decreasing microrna expression for the treatment of neoplasia
WO2006138145A1 (en)	2005-06-14	2006-12-28	Northwestern University	Nucleic acid functionalized nanoparticles for therapeutic applications
MY144014A (en)	2005-08-11	2011-07-29	Synthetic Genomics Inc	Method for in vitro recombination
US20100015604A1 (en)	2005-08-17	2010-01-21	Evriklia Lianidou	Composition and method for determination of ck19 expression
WO2007027775A2 (en)	2005-08-29	2007-03-08	Isis Pharmaceuticals, Inc.	Methods for use in modulating mir-122a
DK1931780T3 (en)	2005-08-29	2016-01-25	Regulus Therapeutics Inc	Antisense-forbindelser med forøget anti-microrna-aktivitet
EP1762627A1 (de)	2005-09-09	2007-03-14	Qiagen GmbH	Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
US8080534B2 (en)	2005-10-14	2011-12-20	Phigenix, Inc	Targeting PAX2 for the treatment of breast cancer
EP2395076A1 (de)	2005-10-14	2011-12-14	MUSC Foundation For Research Development	Targeting von PAX2 zur Induktion der DEFB1-vermittelten Tumorimmunität und Krebstherapie
AU2006305886C1 (en)	2005-10-28	2011-03-17	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of huntingtin gene
WO2007056326A2 (en) *	2005-11-04	2007-05-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of nav1.8 gene
WO2007056331A2 (en)	2005-11-09	2007-05-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of factor v leiden mutant gene
AU2006318194B2 (en)	2005-11-21	2012-08-09	Isis Pharmaceuticals, Inc.	Modulation of eiF4E-BP2 expression
US7623624B2 (en)	2005-11-22	2009-11-24	Illumina, Inc.	Method and apparatus for labeling using optical identification elements characterized by X-ray diffraction
EP1974052A2 (de) *	2005-12-21	2008-10-01	Yale University	Verfahren und zusammensetzungen in verbindung mit der modulation von riboschaltern
JP5713377B2 (ja)	2005-12-28	2015-05-07	ザスクリプスリサーチインスティテュート	薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物
SI2161038T1 (sl)	2006-01-26	2014-05-30	Isis Pharmaceuticals, Inc.	Sestavki in njihove uporabe, usmerjeni proti huntingtinu
US8129515B2 (en)	2006-01-27	2012-03-06	Isis Pharmaceuticals, Inc.	Oligomeric compounds and compositions for the use in modulation of microRNAs
US7569686B1 (en)	2006-01-27	2009-08-04	Isis Pharmaceuticals, Inc.	Compounds and methods for synthesis of bicyclic nucleic acid analogs
ES2351674T3 (es)	2006-01-27	2011-02-09	Isis Pharmaceuticals, Inc.	Análogos de ácidos nucleicos bicíclicos modificados en la posición 6.
US20090305262A1 (en) *	2006-03-31	2009-12-10	Canon Kabushiki Kaisha	Probe, probe set, probe-immobilized carrier, and genetic testing method
CA2647728C (en)	2006-03-31	2014-12-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of eg5 gene
US7830575B2 (en)	2006-04-10	2010-11-09	Illumina, Inc.	Optical scanner with improved scan time
WO2007130434A2 (en) *	2006-05-02	2007-11-15	Applera Corporation	Variable volume dispenser and method
MX2008014005A (es) *	2006-05-03	2009-01-27	Baltic Technology Dev Ltd	Agentes antisentido que combinan un oligonucleotido modificado con base fuertemente unida y nucleasa artificial.
DK2021472T3 (da)	2006-05-05	2011-09-19	Isis Pharmaceuticals Inc	Forbindelser og fremgangsmåder til modulering af genekspression
EP2505648A1 (de)	2006-05-05	2012-10-03	Isis Pharmaceuticals, Inc.	Verbindungen und Verfahren zur Modulation der Expression von PTP1B
US7666854B2 (en) *	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
CA2651453C (en)	2006-05-11	2014-10-14	Isis Pharmaceuticals, Inc.	5'-modified bicyclic nucleic acid analogs
CA2652770A1 (en)	2006-05-19	2007-11-29	Alnylam Pharmaceuticals, Inc.	Rnai modulation of aha and therapeutic uses thereof
CA2653451C (en)	2006-05-22	2015-12-29	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of ikk-b gene
EP2023938A4 (de) *	2006-05-23	2010-11-10	Isis Pharmaceuticals Inc	Modulation von chrebp-expression
WO2008097328A2 (en) *	2006-06-23	2008-08-14	Northwestern University	Asymmetric functionalized nanoparticles and methods of use
WO2008011473A2 (en)	2006-07-19	2008-01-24	Isis Pharmaceuticals, Inc.	Compositions and their uses directed to hbxip
JP2010500290A (ja) *	2006-08-04	2010-01-07	アイシスファーマシューティカルズ，インコーポレーテッド	Ｊｎｋタンパク質を調節するための組成物および方法
US20090047673A1 (en) *	2006-08-22	2009-02-19	Cary Robert B	Miniaturized lateral flow device for rapid and sensitive detection of proteins or nucleic acids
WO2008033866A2 (en) *	2006-09-11	2008-03-20	Yale University	Methods and compositions for the use of lysine riboswitches
JP5560039B2 (ja)	2006-10-05	2014-07-23	マサチューセッツインスティテュートオブテクノロジー	ハイスループット分析のための多機能のコード化された粒子
CA2667055C (en)	2006-10-18	2017-05-09	Isis Pharmaceuticals, Inc.	Antisense compounds
EP2104516B1 (de)	2006-11-01	2015-01-07	University of Rochester	Verfahren und zusammensetzungen in zusammenhang mit der struktur und funktion von apobec3g
US8093222B2 (en)	2006-11-27	2012-01-10	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
EP2455471A3 (de) *	2006-11-27	2012-09-12	Isis Pharmaceuticals, Inc.	Verfahren zur Behandlung von Hypercholesterinämie
CN101600451A (zh)	2006-12-11	2009-12-09	犹他大学研究基金会	用于治疗病理性血管生成和血管通透性的组合物和方法
US20100129358A1 (en)	2006-12-22	2010-05-27	University Of Utah Research Foundation	Method of detecting ocular diseases and pathologic conditions and treatment of same
WO2009045469A2 (en)	2007-10-02	2009-04-09	Amgen Inc.	Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
AU2008212820B2 (en)	2007-02-09	2014-01-30	Northwestern University	Particles for detecting intracellular targets
CA2679586A1 (en) *	2007-02-27	2008-10-23	Northwestern University	Molecule attachment to nanoparticles
JP2010521977A (ja)	2007-03-22	2010-07-01	イェールユニバーシティー	オルタナティブスプライシングを調節するリボスイッチに関する方法および組成物
JP5350360B2 (ja)	2007-03-29	2013-11-27	アルナイラムファーマシューティカルズ，インコーポレイテッド	エボラ由来の遺伝子の発現を阻害するための組成物および方法
US20110091377A1 (en)	2007-05-11	2011-04-21	The Johns Hopkins University	Biomarkers for melanoma
WO2008156987A2 (en)	2007-05-29	2008-12-24	Yale University	Riboswitches and methods and compositions for use of and with riboswitches
WO2008150884A1 (en) *	2007-05-29	2008-12-11	Yale University	Methods and compositions related to riboswitches that control alternative splicing and rna processing
AU2008259907B2 (en)	2007-05-30	2014-12-04	Northwestern University	Nucleic acid functionalized nanoparticles for therapeutic applications
EP2170917B1 (de)	2007-05-30	2012-06-27	Isis Pharmaceuticals, Inc.	Über n-substituiertes aminomethylen verbrückte, bicyclische nukleinsäureanaloga
US7807372B2 (en) *	2007-06-04	2010-10-05	Northwestern University	Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
EP2173760B2 (de)	2007-06-08	2015-11-04	Isis Pharmaceuticals, Inc.	Carbozyklische bizyklische nukleinsäureanaloga
EP2176280B2 (de) *	2007-07-05	2015-06-24	Isis Pharmaceuticals, Inc.	6-disubstituierte bizyklische nukleinsäureanaloga
WO2009023855A2 (en)	2007-08-15	2009-02-19	Isis Pharmaceuticals, Inc.	Tetrahydropyran nucleic acid analogs
EP2195331B1 (de)	2007-08-28	2013-11-20	Uab Research Foundation	Synthetische, apolipoprotein e nachahmende polypeptide und anwendungsverfahren
US8557767B2 (en)	2007-08-28	2013-10-15	Uab Research Foundation	Synthetic apolipoprotein E mimicking polypeptides and methods of use
US8445217B2 (en)	2007-09-20	2013-05-21	Vanderbilt University	Free solution measurement of molecular interactions by backscattering interferometry
US7951785B2 (en) *	2007-09-21	2011-05-31	California Institute Of Technology	NFIA in glial fate determination, glioma therapy and astrocytoma treatment
WO2009060124A2 (en) *	2007-11-05	2009-05-14	Baltic Technology Development, Ltd.	Use of oligonucleotides with modified bases in hybridization of nucleic acids
EP2222851B1 (de) *	2007-11-20	2017-06-28	Ionis Pharmaceuticals, Inc.	Modulation der cd40-expression
EP2848688A1 (de)	2007-12-10	2015-03-18	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und Verfahren zur Hemmung der Faktor VII-Genexpression
JP5749494B2 (ja)	2008-01-02	2015-07-15	テクミラファーマシューティカルズコーポレイション	核酸の送達のための改善された組成物および方法
WO2009100320A2 (en) *	2008-02-07	2009-08-13	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexitol nucleic acid analogs
US20090215050A1 (en) *	2008-02-22	2009-08-27	Robert Delmar Jenison	Systems and methods for point-of-care amplification and detection of polynucleotides
AU2009221775B2 (en)	2008-03-05	2015-05-07	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of Eg5 and VEGF genes
US8426378B2 (en) *	2008-03-21	2013-04-23	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising tricyclic nucelosides and methods for their use
EP2105145A1 (de) *	2008-03-27	2009-09-30	ETH Zürich	Verfahren zur muskelspezifischen Abgabe lipidkonjugierter Oligonukleotide
WO2009124238A1 (en) *	2008-04-04	2009-10-08	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
US8846639B2 (en) *	2008-04-04	2014-09-30	Isis Pharmaceutical, Inc.	Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
EP3604533A1 (de)	2008-04-11	2020-02-05	Arbutus Biopharma Corporation	Ortsspezifische abgabe von nukleinsäuren durch kombination von gerichteten liganden mit endosomolytischen komponenten
DK2281042T3 (en)	2008-04-18	2015-11-09	Baxter Int	Microsphere-based composition for preventing and / or deletion of starting autoimmune diabetes
US8324366B2 (en)	2008-04-29	2012-12-04	Alnylam Pharmaceuticals, Inc.	Compositions and methods for delivering RNAI using lipoproteins
JP2011523401A (ja) *	2008-04-29	2011-08-11	ワイス・エルエルシー	炎症を治療するための方法
WO2009137059A1 (en)	2008-05-05	2009-11-12	Los Alamos National Security, Llc	Highly simplified lateral flow-based nucleic acid sample preparation and passive fluid flow control
US8222221B2 (en)	2008-06-04	2012-07-17	The Board Of Regents Of The University Of Texas System	Modulation of gene expression through endogenous small RNA targeting of gene promoters
CA2732343C (en)	2008-07-29	2017-05-09	The Board Of Regents Of The University Of Texas System	Selective inhibition of polyglutamine protein expression
US20110237646A1 (en) *	2008-08-07	2011-09-29	Isis Pharmaceuticals, Inc.	Modulation of transthyretin expression for the treatment of cns related disorders
ES2657696T3 (es)	2008-08-25	2018-03-06	Excaliard Pharmaceuticals, Inc.	Método para reducir la cicatrización durante la curación de una herida utilizando compuestos antisentido dirigidos al CTGF
SG196769A1 (en)	2008-08-25	2014-02-13	Excaliard Pharmaceuticals Inc	Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
EP3208337A1 (de)	2008-09-02	2017-08-23	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen zur kombinationshemmung der expression eines mutanten egfr und il-6
EP2342616A2 (de)	2008-09-23	2011-07-13	Alnylam Pharmaceuticals Inc.	Chemische modifikationen von monomeren und oligonukleotiden mit cycloaddition
US8501805B2 (en) *	2008-09-24	2013-08-06	Isis Pharmaceuticals, Inc.	Substituted alpha-L-bicyclic nucleosides
EP2361256B1 (de)	2008-09-24	2013-04-10	Isis Pharmaceuticals, Inc.	Cyclohexenylverbindungen als nukleinsäureanaloga
WO2010036962A1 (en)	2008-09-25	2010-04-01	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
JP5777519B2 (ja)	2008-10-09	2015-09-09	テクミラファーマシューティカルズコーポレイション	改良されたアミノ脂質および核酸の送達方法
EP2379084B1 (de)	2008-10-15	2017-11-22	Ionis Pharmaceuticals, Inc.	Modulation der expression von faktor 11
AU2009307677C1 (en)	2008-10-20	2022-09-22	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of transthyretin
WO2010048585A2 (en)	2008-10-24	2010-04-29	Isis Pharmaceuticals, Inc.	Oligomeric compounds and methods
CA2741294C (en)	2008-10-24	2018-04-24	Isis Pharmaceuticals, Inc.	5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
EP4241767B1 (de)	2008-11-10	2024-10-23	Arbutus Biopharma Corporation	Neuartige lipide und zusammensetzungen zur verabreichung von therapeutika
DK2365803T3 (en)	2008-11-24	2018-01-22	Univ Northwestern	POLYVALENT RNA NANOPARTICLE COMPOSITIONS
KR101866152B1 (ko)	2008-12-04	2018-06-08	큐알엔에이, 인크.	종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
CN102307997B (zh)	2008-12-04	2018-03-30	库尔纳公司	通过抑制针对沉默调节蛋白1的天然反义转录物来治疗沉默调节蛋白1(sirt1)相关的疾病
KR101829469B1 (ko)	2008-12-04	2018-03-30	큐알엔에이, 인크.	Ｅｐｏ에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(ｅｐｏ) 관련된 질환의 치료
CA2746514C (en)	2008-12-10	2018-11-27	Alnylam Pharmaceuticals, Inc.	Gnaq targeted dsrna compositions and methods for inhibiting expression
CN102307470B (zh) *	2009-01-08	2015-05-20	西北大学	通过多价寡核苷酸修饰的纳米颗粒缀合物抑制细菌蛋白的产生
US20100233270A1 (en) *	2009-01-08	2010-09-16	Northwestern University	Delivery of Oligonucleotide-Functionalized Nanoparticles
KR101546673B1 (ko) *	2009-01-15	2015-08-25	삼성전자주식회사	전자 사진용 토너 및 그의 제조방법
US20120101148A1 (en)	2009-01-29	2012-04-26	Alnylam Pharmaceuticals, Inc.	lipid formulation
US20120021515A1 (en)	2009-02-06	2012-01-26	Swayze Eric E	Oligomeric compounds and methods
US8536320B2 (en)	2009-02-06	2013-09-17	Isis Pharmaceuticals, Inc.	Tetrahydropyran nucleic acid analogs
WO2010093906A2 (en)	2009-02-12	2010-08-19	Curna, Inc.	Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
WO2010093904A2 (en)	2009-02-12	2010-08-19	Curna, Inc.	Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
WO2010099341A1 (en)	2009-02-26	2010-09-02	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of mig-12 gene
EP3424939A1 (de)	2009-03-02	2019-01-09	Alnylam Pharmaceuticals Inc.	Chemische nukleinsäuremodifikationen
US20110319317A1 (en)	2009-03-04	2011-12-29	Opko Curna, Llc	Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1
AU2010223967B2 (en)	2009-03-12	2015-07-30	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
EP2408919B1 (de)	2009-03-16	2017-10-18	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem nuklearfaktor (erythroid-derived)-like 2 (nrf2) mittels hemmung des natürlichen antisense-transkripts gegen nrf2
EP2408920B1 (de)	2009-03-17	2017-03-08	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem delta-like-1-homolog (dlk1) mittels hemmung des natürlichen antisense-transkripts gegen dlk1
CN102449170A (zh)	2009-04-15	2012-05-09	西北大学	寡核苷酸功能化的纳米颗粒的递送
EP3248618A1 (de)	2009-04-22	2017-11-29	Massachusetts Institute Of Technology	Angeborene immununterdrückung mit ermöglichung der wiederholten verabreichung von langen rna-molekülen
US8815586B2 (en)	2009-04-24	2014-08-26	The Board Of Regents Of The University Of Texas System	Modulation of gene expression using oligomers that target gene regions downstream of 3′ untranslated regions
EP2424987B1 (de)	2009-05-01	2017-11-15	CuRNA, Inc.	Behandlung von hämoglobin (hbf / hbg) verwandten krankheiten durch die inhibition des natürlichen antisense transcripts zu hbf / hbg
SG176553A1 (en)	2009-05-05	2012-01-30	Muthiah Manoharan	Lipid compositions
CA2760706C (en)	2009-05-05	2019-08-06	Alnylam Pharmaceuticals, Inc.	Methods of delivering oligonucleotides to immune cells
WO2010129746A2 (en)	2009-05-06	2010-11-11	Curna, Inc.	Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
CN102459596B (zh)	2009-05-06	2016-09-07	库尔纳公司	通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
US20120107331A1 (en)	2009-05-15	2012-05-03	Yale University	Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
WO2010135329A2 (en)	2009-05-18	2010-11-25	Curna, Inc.	Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
CN102549158B (zh)	2009-05-22	2017-09-26	库尔纳公司	通过抑制针对转录因子e3(tfe3)的天然反义转录物来治疗tfe3和胰岛素受体底物蛋白2(irs2)相关的疾病
CA2764683A1 (en)	2009-05-28	2010-12-02	Joseph Collard	Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
TR201811076T4 (tr)	2009-06-10	2018-08-27	Arbutus Biopharma Corp	Geliştirilmiş lipit formulasyonu.
CN102612560B (zh)	2009-06-16	2017-10-17	库尔纳公司	通过抑制针对对氧磷酶1(pon1)的天然反义转录物来治疗pon1相关的疾病
JP5944311B2 (ja)	2009-06-16	2016-07-05	クルナ・インコーポレーテッド	コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療
CN115227709A (zh)	2009-06-17	2022-10-25	冷泉港实验室	用于在对象中调节smn2剪接的组合物和方法
US8859515B2 (en)	2009-06-24	2014-10-14	Curna, Inc.	Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2
CA2765815A1 (en)	2009-06-26	2010-12-29	Opko Curna, Llc	Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
JP6128848B2 (ja)	2009-08-05	2017-05-17	クルナ・インコーポレーテッド	インスリン遺伝子（ｉｎｓ）に対する天然アンチセンス転写物の抑制によるインスリン遺伝子（ｉｎｓ）関連疾患の治療
US9012421B2 (en)	2009-08-06	2015-04-21	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexose nucleic acid analogs
EP2464336A4 (de)	2009-08-14	2013-11-20	Alnylam Pharmaceuticals Inc	Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der expression eines gens aus dem ebolavirus
WO2011022420A1 (en)	2009-08-17	2011-02-24	Yale University	Methylation biomarkers and methods of use
KR101892760B1 (ko)	2009-08-25	2018-08-28	큐알엔에이, 인크.	ＩＱＧＡＰ에 대한 천연 안티센스 전사체의 억제에 의한 ＧＴＰａｓｅ 활성화 단백질을 함유하는 ＩＱ 모티프(ＩＱＧＡＰ)와 관련된 질환의 치료
DK2473522T3 (en)	2009-09-02	2016-11-28	Genentech Inc	Smoothened MUTANT AND METHODS OF USING THE SAME
BR112012009409A2 (pt)	2009-10-22	2017-02-21	Genentech Inc	método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
EP2494066B1 (de) *	2009-10-27	2017-04-05	Swift Biosciences, Inc.	Bimolekulare primer
JP5866119B2 (ja)	2009-10-30	2016-02-17	ノースウェスタンユニバーシティ	鋳型ナノ複合体
WO2011053994A1 (en)	2009-11-02	2011-05-05	Alnylam Pharmaceuticals, Inc.	Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
US20130084565A1 (en)	2009-11-03	2013-04-04	University Of Virginia Patent Foundation	Versatile, visible method for detecting polymeric analytes
EP2504450B1 (de)	2009-11-23	2016-07-06	Swift Biosciences, Inc.	Vorrichtung zur erweiterung von einsträngigen zielmolekülen
PE20121584A1 (es)	2009-11-30	2012-11-29	Genentech Inc	Composiciones y metodos para el diagnostico y el tratamiento de tumores
WO2011071860A2 (en)	2009-12-07	2011-06-16	Alnylam Pharmaceuticals, Inc.	Compositions for nucleic acid delivery
WO2011084455A2 (en)	2009-12-16	2011-07-14	Opko Curna, Llc.	Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
EP3494963A1 (de)	2009-12-18	2019-06-12	The University of British Columbia	Verfahren und zusammensetzungen zur abgabe von nukleinsäuren
JP6031356B2 (ja)	2009-12-23	2016-11-24	カッパーアールエヌエー，インコーポレイテッド	Ｕｃｐ２に対する天然アンチセンス転写産物の阻害による脱共役タンパク質２（ｕｃｐ２）関連疾患の治療
ES2661387T3 (es)	2009-12-23	2018-03-28	Curna, Inc.	Tratamiento de enfermedades relacionadas con el factor de crecimiento de hepatocitos (hgf) mediante inhibición del transcrito antisentido natural a hgf
US8962585B2 (en)	2009-12-29	2015-02-24	Curna, Inc.	Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
KR101838305B1 (ko)	2009-12-29	2018-03-13	큐알엔에이, 인크.	ＮＲＦ1(ＮｕｃｌｅａｒＲｅｓｐｉｒａｔｏｒｙＦａｃｔｏｒ 1)에 대한 천연 안티센스 전사체의 억제에 의한 핵 호흡 인자 1 관련된 질환의 치료
EP2521784B1 (de)	2010-01-04	2017-12-06	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem interferonregulierungsfaktor 8 (irf8) mittels hemmung des natürlichen antisense-transkripts gegen irf8
CN102822342B (zh)	2010-01-06	2017-05-10	库尔纳公司	通过抑制胰腺发育基因的天然反义转录物而治疗胰腺发育基因相关疾病
US9200277B2 (en)	2010-01-11	2015-12-01	Curna, Inc.	Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
WO2011085102A1 (en)	2010-01-11	2011-07-14	Isis Pharmaceuticals, Inc.	Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2524042A2 (de)	2010-01-12	2012-11-21	Yale University	Strukturierte rna-motive sowie verbindungen und verfahren zu ihrer verwendung
BR112012017483A2 (pt) *	2010-01-14	2019-09-24	Haplomics Inc	previsão e redução de aloimunogenicidade de terapêuticos de proteína
CN102782135A (zh)	2010-01-25	2012-11-14	库尔纳公司	通过抑制rna酶h1的天然反义转录物而治疗rna酶h1相关疾病
WO2011094580A2 (en)	2010-01-28	2011-08-04	Alnylam Pharmaceuticals, Inc.	Chelated copper for use in the preparation of conjugated oligonucleotides
WO2011100131A2 (en)	2010-01-28	2011-08-18	Alnylam Pharmacuticals, Inc.	Monomers and oligonucleotides comprising cycloaddition adduct(s)
WO2011097388A1 (en)	2010-02-03	2011-08-11	Alnylam Pharmaceuticals, Inc.	Selective inhibition of polyglutamine protein expression
CA2824843A1 (en)	2010-02-04	2011-08-11	Ico Therapeutics Inc.	Dosing regimens for treating and preventing ocular disorders using c-raf antisense
WO2011103528A2 (en)	2010-02-22	2011-08-25	Opko Curna Llc	Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
WO2011105900A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011105901A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 9 (c9) and uses thereof
WO2011105902A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-beta (c8-beta) and uses thereof
NZ601293A (en)	2010-02-23	2014-10-31	Genentech Inc	Compositions and methods for the diagnosis and treatment of tumor
WO2011112516A1 (en)	2010-03-08	2011-09-15	Ico Therapeutics Inc.	Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
WO2011112732A2 (en)	2010-03-12	2011-09-15	The Brigham And Women's Hospital, Inc.	Methods of treating vascular inflammatory disorders
WO2011113054A2 (en)	2010-03-12	2011-09-15	Aurasense Llc	Crosslinked polynucleotide structure
WO2011115818A1 (en)	2010-03-17	2011-09-22	Isis Pharmaceuticals, Inc.	5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011120046A2 (en)	2010-03-26	2011-09-29	Swift Biosciences, Inc.	Methods and compositions for isolating polynucleotides
EP2553123B1 (de)	2010-03-26	2016-08-24	Integrated DNA Technologies, Inc.	Verfahren zur verstärkung einer nukleinsäurehybridisierung
US9506057B2 (en)	2010-03-26	2016-11-29	Integrated Dna Technologies, Inc.	Modifications for antisense compounds
CA2792291A1 (en)	2010-03-29	2011-10-06	Kumamoto University	Sirna therapy for transthyretin (ttr) related ocular amyloidosis
WO2011123621A2 (en)	2010-04-01	2011-10-06	Alnylam Pharmaceuticals Inc.	2' and 5' modified monomers and oligonucleotides
AU2011237630B2 (en)	2010-04-06	2016-01-21	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of CD274/PD-L1 gene
KR101900962B1 (ko)	2010-04-09	2018-09-20	큐알엔에이, 인크.	섬유아세포 성장 인자 21 (ｆｇｆ21)에 대한 자연 안티센스 전사체의 저해에 의한 섬유아세포 성장 인자 21 (ｆｇｆ21) 관련된 질환의 치료
WO2011133695A2 (en)	2010-04-20	2011-10-27	Swift Biosciences, Inc.	Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
US20130260460A1 (en)	2010-04-22	2013-10-03	Isis Pharmaceuticals Inc	Conformationally restricted dinucleotide monomers and oligonucleotides
US10913767B2 (en)	2010-04-22	2021-02-09	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising acyclic and abasic nucleosides and analogs
WO2011133871A2 (en)	2010-04-22	2011-10-27	Alnylam Pharmaceuticals, Inc.	5'-end derivatives
US9156873B2 (en)	2010-04-28	2015-10-13	Isis Pharmaceuticals, Inc.	Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom
EP2601204B1 (de)	2010-04-28	2016-09-07	Ionis Pharmaceuticals, Inc.	Modifizierte nukleoside und daraus hergestellte oligomere verbindungen
EP3091027B1 (de)	2010-04-28	2018-01-17	Ionis Pharmaceuticals, Inc.	5'-modifizierte nukleoside und daraus hergestellte oligomere verbindungen
HRP20170737T1 (hr)	2010-04-29	2017-07-28	Ionis Pharmaceuticals, Inc.	Modulacija ekspresije transtiretina
US20130156845A1 (en)	2010-04-29	2013-06-20	Alnylam Pharmaceuticals, Inc.	Lipid formulated single stranded rna
WO2011139387A1 (en)	2010-05-03	2011-11-10	Opko Curna, Llc	Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
CN102958941A (zh)	2010-05-03	2013-03-06	霍夫曼-拉罗奇有限公司	用于肿瘤诊断和治疗的组合物和方法
TWI531370B (zh)	2010-05-14	2016-05-01	可娜公司	藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
US20130203045A1 (en)	2010-05-26	2013-08-08	University Of Virginia Patent Foundation	Method for detecting nucleic acids based on aggregate formation
CA2799207C (en)	2010-05-26	2019-03-26	Curna, Inc.	Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
US9944671B2 (en)	2010-06-02	2018-04-17	Alnylam Pharmaceuticals, Inc.	Compositions and methods directed to treating liver fibrosis
WO2011156278A1 (en)	2010-06-07	2011-12-15	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
US9476101B2 (en)	2010-06-07	2016-10-25	Firefly Bioworks, Inc.	Scanning multifunctional particles
WO2011156202A1 (en)	2010-06-08	2011-12-15	Isis Pharmaceuticals, Inc.	Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
US9638632B2 (en)	2010-06-11	2017-05-02	Vanderbilt University	Multiplexed interferometric detection system and method
US20130236968A1 (en)	2010-06-21	2013-09-12	Alnylam Pharmaceuticals, Inc.	Multifunctional copolymers for nucleic acid delivery
US9168297B2 (en)	2010-06-23	2015-10-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Regulation of skin pigmentation by neuregulin-1 (NRG-1)
NO2593547T3 (de)	2010-07-14	2018-04-14
EP3489360A3 (de)	2010-07-19	2019-08-28	Ionis Pharmaceuticals, Inc.	Modulation einer kern-rna
WO2012016188A2 (en)	2010-07-30	2012-02-02	Alnylam Pharmaceuticals, Inc.	Methods and compositions for delivery of active agents
US20130323269A1 (en)	2010-07-30	2013-12-05	Muthiah Manoharan	Methods and compositions for delivery of active agents
WO2012021554A1 (en)	2010-08-09	2012-02-16	Yale University	Cyclic di-gmp-ii riboswitches, motifs, and compounds, and methods for their use
EP2614149B1 (de)	2010-09-07	2015-04-08	Integrated Dna Technologies, Inc.	Modifizierungen für antisense-verbindungen
SG10201508118WA (en)	2010-09-30	2015-11-27	Agency Science Tech & Res	Methods and reagents for detection and treatment of esophageal metaplasia
AU2011312205B2 (en)	2010-10-05	2015-08-13	Curis, Inc.	Mutant smoothened and methods of using the same
CA2813901C (en)	2010-10-06	2019-11-12	Curna, Inc.	Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
CN103517990A (zh)	2010-10-07	2014-01-15	通用医疗公司	癌症生物标志物
JP6049623B2 (ja)	2010-10-22	2016-12-21	カッパーアールエヌエー，インコーポレイテッド	α‐Ｌ‐イズロニダーゼ（ＩＤＵＡ）への天然アンチセンス転写物の阻害によるＩＤＵＡ関連疾患の治療
CA2816056A1 (en)	2010-10-27	2012-05-03	Curna, Inc.	Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1
CN110123830A (zh)	2010-11-09	2019-08-16	阿尔尼拉姆医药品有限公司	用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
AU2011325956B2 (en)	2010-11-12	2016-07-14	The General Hospital Corporation	Polycomb-associated non-coding RNAs
WO2012068405A2 (en)	2010-11-17	2012-05-24	Isis Pharmaceuticals, Inc.	Modulation of alpha synuclein expression
WO2012071238A2 (en)	2010-11-23	2012-05-31	Opko Curna Llc	Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
US9150926B2 (en)	2010-12-06	2015-10-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Diagnosis and treatment of adrenocortical tumors using human microRNA-483
US9193973B2 (en)	2010-12-10	2015-11-24	Alynylam Pharmaceuticals, Inc.	Compositions and methods for increasing erythropoietin (EPO) production
EP2648763A4 (de)	2010-12-10	2014-05-14	Alnylam Pharmaceuticals Inc	Zusammensetzungen und verfahren zur expressionshemmung der gene klf-1 und bcl11a
JP5902197B2 (ja)	2011-01-11	2016-04-13	アルニラム・ファーマシューティカルズ・インコーポレーテッド	Ｐｅｇ化脂質および薬剤送達のためのそれらの使用
EP2663323B1 (de)	2011-01-14	2017-08-16	The General Hospital Corporation	Verfahren zur anzielung von mir-128 zur regelung des cholesterin-/fettstoffwechsels
DK2670404T3 (en)	2011-02-02	2018-11-19	Univ Princeton	CIRCUIT MODULATORS AS VIRUS PRODUCTION MODULATORS
SI2670411T1 (sl)	2011-02-02	2019-06-28	Excaliard Pharmaceuticals, Inc.	Protismiselne spojine, ki so usmerjene na rastni faktor veznega tkiva (CTGF), za uporabo v postopku zdravljenja keloidov ali hipertrofnih brazgotin
WO2012106591A1 (en)	2011-02-03	2012-08-09	Mirna Therapeutics, Inc.	Synthetic mimics of mir-34
JP2014506789A (ja)	2011-02-03	2014-03-20	マーナセラピューティクスインコーポレイテッド	ｍｉＲ−１２４の合成模倣体
EP3067421B1 (de)	2011-02-08	2018-10-10	Ionis Pharmaceuticals, Inc.	Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
EP2678026B1 (de)	2011-02-21	2016-05-18	The University of Zurich	Ankyrin-g zur verwendung in der behandlung von neurodegenerativer erkrankungen
US9562853B2 (en)	2011-02-22	2017-02-07	Vanderbilt University	Nonaqueous backscattering interferometric methods
MX360349B (es)	2011-03-29	2018-10-30	Alnylam Pharmaceuticals Inc	Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
JP2014511694A (ja)	2011-04-03	2014-05-19	ザジェネラルホスピタルコーポレーションドゥーイングビジネスアズマサチューセッツジェネラルホスピタル	修飾型ｒｎａ（ｍｏｄ−ｒｎａ）を使用する効率的なインビボタンパク質発現
EP2699698B9 (de)	2011-04-20	2020-07-15	Mesa Biotech, Inc.	Oszillierende amplifikationsreaktion für nukleinsäuren
WO2012149154A1 (en)	2011-04-26	2012-11-01	Swift Biosciences, Inc.	Polynucleotide primers and probes
WO2012151268A1 (en)	2011-05-02	2012-11-08	University Of Virginia Patent Foundation	Method and system for high throughput optical and label free detection of analytes
WO2012151289A2 (en)	2011-05-02	2012-11-08	University Of Virginia Patent Foundation	Method and system to detect aggregate formation on a substrate
WO2012170347A1 (en)	2011-06-09	2012-12-13	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
RU2620980C2 (ru)	2011-06-09	2017-05-30	Курна, Инк.	Лечение заболеваний, связанных с фратаксином (fxn), путем ингибирования природного антисмыслового транскрипта fxn
US9315811B2 (en)	2011-06-10	2016-04-19	Ionis Pharmaceuticals, Inc.	Methods for modulating kallikrein (KLKB1) expression
KR20230084331A (ko)	2011-06-21	2023-06-12	알닐람 파마슈티칼스 인코포레이티드	아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법
EP3444348A1 (de)	2011-06-21	2019-02-20	Alnylam Pharmaceuticals, Inc.	Angiopoietin-3 (angptl3)-irna-zusammensetzungen und verfahren zur verwendung davon
EP3388068A1 (de)	2011-06-21	2018-10-17	Alnylam Pharmaceuticals, Inc.	Zusammensetzung und verfahren zur hemmung der expression von protein-c (proc)-genen
WO2012178033A2 (en)	2011-06-23	2012-12-27	Alnylam Pharmaceuticals, Inc.	Serpina1 sirnas: compositions of matter and methods of treatment
AU2012275096B2 (en)	2011-06-29	2016-02-04	Ionis Pharmaceuticals, Inc.	Methods for modulating kallikrein (KLKB1) expression
WO2013019857A2 (en)	2011-08-01	2013-02-07	Alnylam Pharmaceuticals, Inc.	Method for improving the success rate of hematopoietic stem cell transplants
US10202599B2 (en)	2011-08-11	2019-02-12	Ionis Pharmaceuticals, Inc.	Selective antisense compounds and uses thereof
JP2014526517A (ja)	2011-09-14	2014-10-06	ノースウェスタンユニバーシティ	血液脳関門を通過することができるナノ抱合体
JP6129844B2 (ja)	2011-09-14	2017-05-17	ラナセラピューティクスインコーポレイテッド	多量体オリゴヌクレオチド化合物
US9580713B2 (en)	2011-09-17	2017-02-28	Yale University	Fluoride-responsive riboswitches, fluoride transporters, and methods of use
EP2760477B1 (de)	2011-09-27	2018-08-08	Alnylam Pharmaceuticals, Inc.	Substituierte di-aliphatic pegylierte lipide
EP2766482B1 (de)	2011-10-11	2016-12-07	The Brigham and Women's Hospital, Inc.	Mikro-rnas in neurodegenerativen erkrankungen
MX390891B (es)	2011-10-14	2025-03-19	Genentech Inc	ANTICUERPOS ANTI-HtrA1 Y MÉTODOS DE USO.
WO2013059740A1 (en)	2011-10-21	2013-04-25	Foundation Medicine, Inc.	Novel alk and ntrk1 fusion molecules and uses thereof
WO2013090457A2 (en)	2011-12-12	2013-06-20	Oncoimmunin Inc.	In vivo delivery of oligonucleotides
JP2015501844A (ja)	2011-12-16	2015-01-19	モデルナセラピューティクスインコーポレイテッドＭｏｄｅｒｎａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
JP6280045B2 (ja)	2011-12-22	2018-02-14	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	肺腺癌内転移関連性転写物１（ｍｅｔａｓｔａｓｉｓ−ａｓｓｏｃｉａｔｅｄ−ｉｎ−ｌｕｎｇ−ａｄｅｎｏｃａｒｃｉｎｏｍａ−ｔｒａｎｓｃｒｉｐｔ−１：ｍａｌａｔ−１）の発現調節法
EP3330278A1 (de)	2012-02-08	2018-06-06	Ionis Pharmaceuticals, Inc.	Modulation von rna durch wiederholtes targeting
CN108300765B (zh)	2012-03-13	2022-01-11	斯威夫特生物科学公司	用于通过核酸聚合酶对衬底多核苷酸进行大小受控的同聚物加尾的方法和组合物
EP2825648B1 (de)	2012-03-15	2018-09-05	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem brain-derived neurotrophen faktor (bdnf) mittels hemmung des natürlichen antisense-transkripts gegen bdnf
WO2013138662A1 (en)	2012-03-16	2013-09-19	4S3 Bioscience, Inc.	Antisense conjugates for decreasing expression of dmpk
WO2013142514A1 (en)	2012-03-19	2013-09-26	Isis Pharmaceuticals, Inc.	Methods and compositions for modulating alpha-1-antitrypsin expression
WO2013151663A1 (en)	2012-04-02	2013-10-10	modeRNA Therapeutics	Modified polynucleotides for the production of membrane proteins
CN108949772A (zh)	2012-04-02	2018-12-07	现代泰克斯公司	用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
EP2850092B1 (de)	2012-04-09	2017-03-01	Ionis Pharmaceuticals, Inc.	Tricyclische nukleinsäureanaloga
WO2013154799A1 (en)	2012-04-09	2013-10-17	Isis Pharmaceuticals, Inc.	Tricyclic nucleosides and oligomeric compounds prepared therefrom
US9133461B2 (en)	2012-04-10	2015-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the ALAS1 gene
EP2839006B1 (de)	2012-04-20	2018-01-03	Ionis Pharmaceuticals, Inc.	Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
CN104704122A (zh)	2012-04-20	2015-06-10	艾珀特玛治疗公司	产热的miRNA调节剂
US9127274B2 (en)	2012-04-26	2015-09-08	Alnylam Pharmaceuticals, Inc.	Serpinc1 iRNA compositions and methods of use thereof
WO2013163628A2 (en)	2012-04-27	2013-10-31	Duke University	Genetic correction of mutated genes
US9273949B2 (en)	2012-05-11	2016-03-01	Vanderbilt University	Backscattering interferometric methods
CN104583398A (zh)	2012-05-16	2015-04-29	Rana医疗有限公司	用于调节基因表达的组合物和方法
KR20150030205A (ko)	2012-05-16	2015-03-19	라나 테라퓨틱스, 인크.	Smn 유전자 패밀리 발현을 조절하기 위한 조성물 및 방법
WO2013177248A2 (en)	2012-05-22	2013-11-28	Isis Pharmaceuticals, Inc.	Modulation of enhancer rna mediated gene expression
JP6294876B2 (ja)	2012-06-25	2018-03-14	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Ｕｂｅ３ａ−ａｔｓ発現の調節
US20140038182A1 (en)	2012-07-17	2014-02-06	Dna Logix, Inc.	Cooperative primers, probes, and applications thereof
ES2773489T3 (es)	2012-07-27	2020-07-13	Ionis Pharmaceuticals Inc	Modulación de enfermedades relacionadas con el sistema renina-angiotensina (RAS) mediante angiotensinógenos
CA2880833A1 (en)	2012-08-03	2014-02-06	Aptamir Therapeutics, Inc.	Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
US9403865B2 (en)	2012-08-15	2016-08-02	Ionis Pharmaceuticals, Inc.	Method of preparing oligomeric compounds using modified capping protocols
WO2014045126A2 (en)	2012-09-18	2014-03-27	Uti Limited Partnership	Treatment of pain by inhibition of usp5 de-ubiquitinase
WO2014059353A2 (en)	2012-10-11	2014-04-17	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleosides and uses thereof
AR092982A1 (es)	2012-10-11	2015-05-13	Isis Pharmaceuticals Inc	Modulacion de la expresion de receptores androgenicos
EP4052709A1 (de)	2012-10-11	2022-09-07	Ionis Pharmaceuticals, Inc.	Verfahren zur behandlung der kennedy-krankheit
US9029335B2 (en)	2012-10-16	2015-05-12	Isis Pharmaceuticals, Inc.	Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
CA2887702C (en)	2012-10-26	2023-08-01	Geron Corporation	C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
AU2013337277B2 (en)	2012-11-05	2018-03-08	Foundation Medicine, Inc.	Novel NTRK1 fusion molecules and uses thereof
WO2014071419A2 (en)	2012-11-05	2014-05-08	Foundation Medicine, Inc.	Novel fusion molecules and uses thereof
ES2921623T3 (es)	2012-11-26	2022-08-30	Modernatx Inc	ARN modificado terminalmente
US10272163B2 (en)	2012-12-07	2019-04-30	The Regents Of The University Of California	Factor VIII mutation repair and tolerance induction
JP2016504050A (ja)	2013-01-17	2016-02-12	モデルナセラピューティクスインコーポレイテッドＭｏｄｅｒｎａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	細胞表現型の改変のためのシグナルセンサーポリヌクレオチド
WO2014113729A2 (en)	2013-01-18	2014-07-24	Foundation Mecicine, Inc.	Methods of treating cholangiocarcinoma
US9701708B2 (en)	2013-01-31	2017-07-11	Ionis Pharmaceuticals, Inc.	Method of preparing oligomeric compounds using modified coupling protocols
KR102169899B1 (ko)	2013-02-14	2020-10-26	아이오니스 파마수티컬즈, 인코포레이티드	지질단백질 리파제 결핍 (lpld) 모집단에서 아포지질단백질 c-iii (apociii) 발현의 조절
US20150366890A1 (en)	2013-02-25	2015-12-24	Trustees Of Boston University	Compositions and methods for treating fungal infections
EP2961853B1 (de)	2013-02-28	2018-09-19	The Board of Regents of The University of Texas System	Verfahren zur klassifizierung einer krebserkrankung als anfälligkeit für tmepai-gerichtete therapien und zur heilung solcher krebserkrankungen
US20160024181A1 (en)	2013-03-13	2016-01-28	Moderna Therapeutics, Inc.	Long-lived polynucleotide molecules
US10258698B2 (en)	2013-03-14	2019-04-16	Modernatx, Inc.	Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
ME03043B (de)	2013-03-14	2018-10-20	Alnylam Pharmaceuticals Inc	Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
US9828582B2 (en)	2013-03-19	2017-11-28	Duke University	Compositions and methods for the induction and tuning of gene expression
US9937231B2 (en)	2013-03-27	2018-04-10	The General Hospital Corporation	Methods and agents for treating Alzheimer's disease
JP2016522679A (ja)	2013-04-04	2016-08-04	プレジデントアンドフェローズオブハーバードカレッジ	ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用
US10590412B2 (en)	2013-04-19	2020-03-17	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulation nucleic acids through nonsense mediated decay
CA2921162A1 (en)	2013-05-01	2014-11-06	Ionis Pharmaceuticals, Inc.	Conjugated antisense compounds and their use
KR102463973B1 (ko)	2013-05-22	2022-11-07	알닐람 파마슈티칼스 인코포레이티드	ＳＥＲＰＩＮＡ1 ｉＲＮＡ 조성물 및 이의 사용 방법
EA201592225A1 (ru)	2013-05-22	2016-04-29	Элнилэм Фармасьютикалз, Инк.	КОМПОЗИЦИИ НА ОСНОВЕ iRNA TMPRSS6 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2014197835A2 (en)	2013-06-06	2014-12-11	The General Hospital Corporation	Methods and compositions for the treatment of cancer
EP3007704B1 (de)	2013-06-13	2021-01-06	Antisense Therapeutics Ltd	Kombinationstherapie der akromegalie
EP3011026B1 (de)	2013-06-21	2019-12-18	Ionis Pharmaceuticals, Inc.	Verbindungen und verfahren zur modulation der apolipoprotein-c-iii-expression zur verbesserung eines diabetischen profils
ES2787600T3 (es)	2013-07-02	2020-10-16	Ionis Pharmaceuticals Inc	Moduladores del receptor de la hormona del crecimiento
HUE056760T2 (hu)	2013-07-11	2022-03-28	Modernatx Inc	A CRISPR-hez kapcsolódó fehérjéket és a szintetikus SGRNS-ket kódoló szintetikus polinukleotidokat tartalmazó készítmények és felhasználási módjaik
WO2015017694A1 (en) *	2013-07-31	2015-02-05	Regents Of The University Of California	Dna double-write/double binding identity
RS59991B1 (sr)	2013-08-08	2020-04-30	Scripps Research Inst	Metoda enzimskog in vitro obeležavanja specifičnog za položaj nukleinskih kiselina uvođenjem neprirodnih nukleotida
TW201536329A (zh)	2013-08-09	2015-10-01	Isis Pharmaceuticals Inc	用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
KR102365486B1 (ko)	2013-08-28	2022-02-18	아이오니스 파마수티컬즈, 인코포레이티드	프리칼리크레인 (pkk) 발현의 조절
WO2015034925A1 (en)	2013-09-03	2015-03-12	Moderna Therapeutics, Inc.	Circular polynucleotides
US20160194625A1 (en)	2013-09-03	2016-07-07	Moderna Therapeutics, Inc.	Chimeric polynucleotides
JP6666250B2 (ja)	2013-09-13	2020-03-13	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	補体ｂ因子の調節薬
CA2925107A1 (en)	2013-10-02	2015-04-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
KR20160067219A (ko)	2013-10-03	2016-06-13	모더나 세라퓨틱스, 인코포레이티드	저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
SG11201602631XA (en)	2013-10-04	2016-05-30	Alnylam Pharmaceuticals Inc	Compositions and methods for inhibiting expression of the alas1 gene
WO2015054451A1 (en)	2013-10-09	2015-04-16	The United States Of America As Represented By The Secretary Department Of Health And Human Services	Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma
US11162096B2 (en)	2013-10-14	2021-11-02	Ionis Pharmaceuticals, Inc	Methods for modulating expression of C9ORF72 antisense transcript
WO2015061246A1 (en)	2013-10-21	2015-04-30	Isis Pharmaceuticals, Inc.	Method for solution phase detritylation of oligomeric compounds
EP3060680B1 (de)	2013-10-21	2019-02-27	The General Hospital Corporation	Verfahren im zusammenhang mit zirkulierenden tumorzellclustern und krebsbehandlung
WO2015066708A1 (en)	2013-11-04	2015-05-07	Northwestern University	Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (sna)
CA3236835A1 (en)	2013-11-22	2015-05-28	Mina Therapeutics Limited	C/ebp alpha short activating rna compositions and methods of use
JP6527516B2 (ja)	2013-12-03	2019-06-05	ノースウェスタンユニバーシティ	リポソーム粒子、前述のものを作製する方法及びその使用
CA2844640A1 (en)	2013-12-06	2015-06-06	The University Of British Columbia	Method for treatment of castration-resistant prostate cancer
WO2015085183A2 (en)	2013-12-06	2015-06-11	Swift Biosciences, Inc.	Cleavable competitor polynucleotides
CA2931090A1 (en)	2013-12-12	2015-06-18	Alnylam Pharmaceuticals, Inc.	Complement component irna compositions and methods of use thereof
AU2014364520B2 (en)	2013-12-20	2020-01-02	The General Hospital Corporation	Methods and assays relating to circulating tumor cells
HUE052243T2 (hu)	2013-12-24	2021-04-28	Ionis Pharmaceuticals Inc	Az angiopoietin-szerû 3 expressziójának modulációja
ES2694857T3 (es)	2014-02-04	2018-12-27	Genentech, Inc.	Smoothened mutante y métodos de uso de la misma
AU2015217301A1 (en)	2014-02-11	2016-08-25	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (KHK) iRNA compositions and methods of use thereof
WO2015142910A1 (en)	2014-03-17	2015-09-24	Isis Pharmaceuticals, Inc.	Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
WO2015143245A1 (en)	2014-03-19	2015-09-24	Isis Pharmaceuticals, Inc.	Methods for modulating ataxin 2 expression
CN116970607A (zh)	2014-03-19	2023-10-31	Ionis制药公司	用于调节共济失调蛋白2表达的组合物
MY192634A (en)	2014-04-01	2022-08-29	Biogen Ma Inc	Compositions for modulating sod-1 expression
TWI638047B (zh)	2014-04-09	2018-10-11	史基普研究協會	藉由核酸三磷酸酯轉運子將非天然或經修飾的核苷三磷酸酯輸入至細胞中
MA39835A (fr)	2014-04-17	2017-02-22	Biogen Ma Inc	Compositions et procédés de modulation de l'épissage du smn2 chez un patient
US10221416B2 (en)	2014-04-24	2019-03-05	Ionis Pharmaceuticals, Inc.	Oligomeric compounds comprising alpha-beta-constrained nucleic acid
MX382230B (es)	2014-05-01	2025-03-13	Ionis Pharmaceuticals Inc	Composiciones y metodos para modular la expresion de similar a la angiopoyetina tipo 3.
AU2015252841B2 (en)	2014-05-01	2020-03-19	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating growth hormone receptor expression
US10280423B2 (en)	2014-05-01	2019-05-07	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating complement factor B expression
JP6665111B2 (ja)	2014-05-01	2020-03-13	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Ｐｋｋ発現を調節するための組成物及び方法
WO2015168514A1 (en)	2014-05-01	2015-11-05	Isis Pharmaceuticals, Inc.	Method for synthesis of reactive conjugate clusters
WO2015171918A2 (en)	2014-05-07	2015-11-12	Louisiana State University And Agricultural And Mechanical College	Compositions and uses for treatment thereof
WO2015175510A1 (en)	2014-05-12	2015-11-19	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating a serpinc1-associated disorder
BR122020023687B1 (pt)	2014-05-22	2023-03-07	Alnylam Pharmaceuticals, Inc	Agente de ácido ribonucleico (rnai) de fita dupla, seus usos e composição farmacêutica
CN106659758A (zh)	2014-06-02	2017-05-10	儿童医疗中心有限公司	用于免疫调节的组合物和方法
WO2015190922A1 (en)	2014-06-10	2015-12-17	Erasmus University Medical Center Rotterdam	Antisense oligonucleotides useful in treatment of pompe disease
EP3760208B1 (de)	2014-06-25	2024-05-29	The General Hospital Corporation	Targeting von humanem satellit ii (hsatii)
EP3169693B1 (de)	2014-07-16	2022-03-09	ModernaTX, Inc.	Chimäre polynukleotide
US9951327B1 (en)	2014-07-17	2018-04-24	Integrated Dna Technologies, Inc.	Efficient and rapid method for assembling and cloning double-stranded DNA fragments
WO2016014846A1 (en)	2014-07-23	2016-01-28	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of intrabodies
CA2954475C (en)	2014-07-31	2023-05-16	Uab Research Foundation	Apoe mimetic peptides and higher potency to clear plasma cholesterol
WO2016028940A1 (en)	2014-08-19	2016-02-25	Northwestern University	Protein/oligonucleotide core-shell nanoparticle therapeutics
WO2016033424A1 (en)	2014-08-29	2016-03-03	Genzyme Corporation	Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
EP4137138A1 (de)	2014-08-29	2023-02-22	Alnylam Pharmaceuticals, Inc.	Verfahren zum behandeln von transthyretin (ttr)-vermittelter amyloidose
ES2985036T3 (es)	2014-08-29	2024-11-04	Childrens Medical Ct Corp	Métodos y composiciones para el tratamiento del cáncer
WO2016040748A1 (en)	2014-09-12	2016-03-17	Ionis Pharmaceuticals, Inc.	Compositions and methods for detection of smn protein in a subject and treatment of a subject
EP3191591A1 (de)	2014-09-12	2017-07-19	Alnylam Pharmaceuticals, Inc.	Gegen komplementkomponente c5 gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
CA2960728C (en)	2014-09-18	2023-06-06	The University Of British Columbia	Allele-specific therapy for huntington disease haplotypes
EP3198012B1 (de)	2014-09-26	2019-09-04	University of Massachusetts	Rna-modulierende stoffe
TWI864340B (zh)	2014-10-10	2024-12-01	美商艾爾妮蘭製藥公司	用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
EP3207138B1 (de)	2014-10-17	2020-07-15	Alnylam Pharmaceuticals, Inc.	Gegen aminolävulinsäuresynthase-1 (alas1) gerichtete polynukleotidmittel und verwendungen davon
EP3904519A1 (de)	2014-10-30	2021-11-03	Genzyme Corporation	Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
SG11201703638XA (en)	2014-11-10	2017-06-29	Alnylam Pharmaceuticals Inc	Hepatitis b virus (hbv) irna compositions and methods of use thereof
EP3218485A1 (de)	2014-11-10	2017-09-20	Glaxosmithkline Intellectual Property (No. 2) Limited	Lang wirkende pharmazeutische zusammensetzungen für hepatitis c
SG11201703646SA (en)	2014-11-10	2017-06-29	Glaxosmithkline Intellectual Property (No 2) Ltd	Combination long acting compositions and methods for hepatitis c
CA2968114A1 (en)	2014-11-17	2016-05-26	Alnylam Pharmaceuticals, Inc.	Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
US11213593B2 (en)	2014-11-21	2022-01-04	Northwestern University	Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US10400243B2 (en)	2014-11-25	2019-09-03	Ionis Pharmaceuticals, Inc.	Modulation of UBE3A-ATS expression
EP3229842B1 (de)	2014-12-08	2022-07-06	The Board of Regents of The University of Texas System	Lipokationische polymere und verwendungen davon
EP3234141A4 (de)	2014-12-18	2018-06-20	Alnylam Pharmaceuticals, Inc.	Reversir-tm-verbindungen
US9688707B2 (en)	2014-12-30	2017-06-27	Ionis Pharmaceuticals, Inc.	Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
WO2016112132A1 (en)	2015-01-06	2016-07-14	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of c9orf72 antisense transcript
WO2016115490A1 (en)	2015-01-16	2016-07-21	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulation of dux4
WO2016118812A1 (en)	2015-01-23	2016-07-28	Vanderbilt University	A robust interferometer and methods of using same
JP6929791B2 (ja)	2015-02-09	2021-09-01	デュークユニバーシティ	エピゲノム編集のための組成物および方法
WO2016130806A2 (en)	2015-02-13	2016-08-18	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
EP3262173A2 (de)	2015-02-23	2018-01-03	Crispr Therapeutics AG	Materialien und verfahren zur behandlung von humangenetischen erkrankungen einschliesslich hämoglobinopathien
WO2016137923A1 (en)	2015-02-23	2016-09-01	Ionis Pharmaceuticals, Inc.	Method for solution phase detritylation of oligomeric compounds
US10426789B2 (en)	2015-02-26	2019-10-01	Ionis Pharmaceuticals, Inc.	Allele specific modulators of P23H rhodopsin
US11129844B2 (en)	2015-03-03	2021-09-28	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating MECP2 expression
AU2016243583B2 (en)	2015-03-27	2022-03-10	President And Fellows Of Harvard College	Modified T cells and methods of making and using the same
HK1249140A1 (zh)	2015-04-03	2018-10-26	Ionis Pharmaceuticals, Inc.	用於调节tmprss6表达的化合物和方法
US10961532B2 (en)	2015-04-07	2021-03-30	The General Hospital Corporation	Methods for reactivating genes on the inactive X chromosome
MX2017012610A (es)	2015-04-08	2018-03-16	Alnylam Pharmaceuticals Inc	Composiciones y metodos para inhibir la expresion del gen lect2.
SI3283080T1 (sl)	2015-04-16	2020-06-30	Ionis Pharmaceuticals, Inc.	Sestavki za moduliranje izražanja C9ORF72
WO2016167780A1 (en)	2015-04-16	2016-10-20	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of c9orf72 antisense transcript
AU2016253147B2 (en)	2015-04-24	2021-07-22	Mesa Biotech, Inc.	Fluidic test cassette
WO2016201301A1 (en)	2015-06-12	2016-12-15	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions and methods of use thereof
EP3310918B1 (de)	2015-06-18	2020-08-05	Alnylam Pharmaceuticals, Inc.	Gegen hydroxysäureoxidase (glycolat-oxidase, hao1) gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
WO2016209862A1 (en)	2015-06-23	2016-12-29	Alnylam Pharmaceuticals, Inc.	Glucokinase (gck) irna compositions and methods of use thereof
CA2990852A1 (en)	2015-06-26	2016-12-29	Beth Israel Deaconess Medical Center, Inc.	Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
IL318703A (en)	2015-06-29	2025-03-01	Caris Science Inc	Therapeutic oligonucleotides
US10494632B2 (en)	2015-07-10	2019-12-03	Alnylam Pharmaceuticals, Inc.	Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
DK3324980T3 (da)	2015-07-17	2022-02-14	Alnylam Pharmaceuticals Inc	Multimålrettede enkeltenhedskonjugater
EP3328873B1 (de)	2015-07-28	2025-09-17	Caris Science, Inc.	Gezielte oligonukleotide
EP3332009A1 (de)	2015-08-04	2018-06-13	Yeda Research and Development Co., Ltd.	Verfahren zum screening auf riboswitches und attenuatoren
CN108368507B (zh)	2015-09-02	2022-03-22	阿尔尼拉姆医药品有限公司	程序性细胞死亡1配体1(PD-L1)的iRNA组合物及其使用方法
CN108271360B (zh)	2015-09-14	2023-01-24	得克萨斯州大学系统董事会	亲脂阳离子树枝状聚合物及其用途
CA2998287A1 (en)	2015-09-24	2017-04-20	Crispr Therapeutics Ag	Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
US10533175B2 (en)	2015-09-25	2020-01-14	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating Ataxin 3 expression
EP4474389A3 (de)	2015-10-08	2025-03-19	Ionis Pharmaceuticals, Inc.	Verbindungen und verfahren zur modulation der angiotensinogenexpression
EP4089175A1 (de)	2015-10-13	2022-11-16	Duke University	Genom-engineering mit typ-i-crispr-systemen in eukaryotischen zellen
AU2016344609B2 (en)	2015-10-28	2022-05-12	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of duchenne muscular dystrophy
SG11201803356SA (en)	2015-10-30	2018-05-30	Genentech Inc	Anti-htra1 antibodies and methods of use thereof
ES2938883T3 (es)	2015-11-05	2023-04-17	Los Angeles Childrens Hospital	Oligo antisentido para su uso en el tratamiento de la leucemia mieloide aguda
EP3371305A1 (de)	2015-11-06	2018-09-12	Crispr Therapeutics AG	Materialien und verfahren zur behandlung der glycogenspeicherkrankheit des typs 1a
EP3370708A4 (de)	2015-11-06	2019-06-26	Ionis Pharmaceuticals, Inc.	Modulation der apolipoprotein (a)-expression
CA3005878A1 (en)	2015-11-19	2017-05-26	The Brigham And Women's Hospital, Inc.	Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
WO2017095967A2 (en)	2015-11-30	2017-06-08	Duke University	Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
AU2016364667A1 (en)	2015-12-01	2018-06-21	Crispr Therapeutics Ag	Materials and methods for treatment of Alpha-1 antitrypsin deficiency
US11058709B1 (en)	2015-12-04	2021-07-13	Ionis Pharmaceuticals, Inc.	Methods of treating breast cancer
CA3007152A1 (en)	2015-12-07	2017-06-15	Erasmus University Medical Center Rotterdam	Enzymatic replacement therapy and antisense therapy for pompe disease
SG11201804729RA (en)	2015-12-07	2018-07-30	Genzyme Corp	Methods and compositions for treating a serpinc1-associated disorder
WO2017106767A1 (en)	2015-12-18	2017-06-22	The Scripps Research Institute	Production of unnatural nucleotides using a crispr/cas9 system
MX2018007840A (es)	2015-12-23	2019-05-02	Crispr Therapeutics Ag	Materiales y metodos para el tratamiento de la esclerosis lateral amiotrofica y/o la degeneracion lobar frontotemporal.
CA3006015A1 (en)	2015-12-31	2017-07-06	Ionis Pharmaceuticals, Inc.	Methods for reducing ataxin-2 expression
AU2017205462A1 (en)	2016-01-05	2018-06-07	Ionis Pharmaceuticals, Inc.	Methods for reducing LRRK2 expression
US10627396B2 (en)	2016-01-29	2020-04-21	Vanderbilt University	Free-solution response function interferometry
WO2017134529A1 (en)	2016-02-02	2017-08-10	Crispr Therapeutics Ag	Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
AU2017213826A1 (en)	2016-02-04	2018-08-23	Curis, Inc.	Mutant smoothened and methods of using the same
WO2017141109A1 (en)	2016-02-18	2017-08-24	Crispr Therapeutics Ag	Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
JP7033072B2 (ja)	2016-02-25	2022-03-09	ザブリガムアンドウィメンズホスピタルインコーポレイテッド	Ｓｍｏｃ２を標的化する線維症のための治療方法
EP3429690A4 (de)	2016-03-16	2019-10-23	Ionis Pharmaceuticals, Inc.	Verfahren zur modulation von keap1
WO2017161168A1 (en)	2016-03-16	2017-09-21	Ionis Pharmaceuticals, Inc.	Modulation of dyrk1b expression
WO2017158422A1 (en)	2016-03-16	2017-09-21	Crispr Therapeutics Ag	Materials and methods for treatment of hereditary haemochromatosis
WO2017161357A1 (en)	2016-03-18	2017-09-21	Caris Science, Inc.	Oligonucleotide probes and uses thereof
EP3443081A4 (de)	2016-04-13	2019-10-30	Duke University	Crispr/cas9-basierte repressoren zur in-vivo-ausschaltung von gen-targets und verfahren zur verwendung
JP6974349B2 (ja)	2016-04-18	2021-12-01	クリスパーセラピューティクスアクチェンゲゼルシャフト	ヘモグロビン異常症の処置のための材料及び方法
WO2017184689A1 (en)	2016-04-19	2017-10-26	Alnylam Pharmaceuticals, Inc.	High density lipoprotein binding protein (hdlbp/vigilin) irna compositions and methods of use thereof
WO2017191503A1 (en)	2016-05-05	2017-11-09	Crispr Therapeutics Ag	Materials and methods for treatment of hemoglobinopathies
AU2017267634C1 (en)	2016-05-16	2022-05-26	The Board Of Regents Of The University Of Texas System	Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
CA3025486A1 (en)	2016-05-25	2017-11-30	Caris Science, Inc.	Oligonucleotide probes and uses thereof
WO2017214518A1 (en)	2016-06-10	2017-12-14	Alnylam Pharmaceuticals, Inc.	COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
CA3023514A1 (en)	2016-06-17	2017-12-21	Ionis Pharmaceuticals, Inc.	Modulation of gys1 expression
EP4163293A1 (de)	2016-06-24	2023-04-12	The Scripps Research Institute	Neuartiger nukleosid-triphosphat-transporter und verwendungen davon
US11174469B2 (en)	2016-06-29	2021-11-16	Crispr Therapeutics Ag	Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
WO2018002812A1 (en)	2016-06-29	2018-01-04	Crispr Therapeutics Ag	Materials and methods for treatment of myotonic dystrophy type 1 (dm1) and other related disorders
US11564997B2 (en)	2016-06-29	2023-01-31	Crispr Therapeutics Ag	Materials and methods for treatment of friedreich ataxia and other related disorders
US11459587B2 (en)	2016-07-06	2022-10-04	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of pain related disorders
CA3029132A1 (en)	2016-07-06	2018-01-11	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of pain related disorders
WO2018007871A1 (en)	2016-07-08	2018-01-11	Crispr Therapeutics Ag	Materials and methods for treatment of transthyretin amyloidosis
AU2017296195A1 (en)	2016-07-11	2019-01-24	Translate Bio Ma, Inc.	Nucleic acid conjugates and uses thereof
EP4275747A3 (de)	2016-07-19	2024-01-24	Duke University	Therapeutische anwendungen von cpf1-basierter genomeditierung
KR20190031306A (ko)	2016-07-21	2019-03-25	맥스시티 인코포레이티드	게놈 dna를 변경하기 위한 방법 및 조성물
WO2018020323A2 (en)	2016-07-25	2018-02-01	Crispr Therapeutics Ag	Materials and methods for treatment of fatty acid disorders
NL2017294B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Natural cryptic exon removal by pairs of antisense oligonucleotides.
NL2017295B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Antisense oligomeric compound for Pompe disease
US11364304B2 (en)	2016-08-25	2022-06-21	Northwestern University	Crosslinked micellar spherical nucleic acids
WO2018055577A1 (en)	2016-09-23	2018-03-29	Synthena Ag	Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
KR20190065341A (ko)	2016-10-06	2019-06-11	아이오니스 파마수티컬즈, 인코포레이티드	올리고머 화합물들의 접합 방법
CA3037046A1 (en)	2016-10-31	2018-05-03	University Of Massachusetts	Targeting microrna-101-3p in cancer therapy
JOP20190104A1 (ar)	2016-11-10	2019-05-07	Ionis Pharmaceuticals Inc	مركبات وطرق لتقليل التعبير عن atxn3
TW202313978A (zh)	2016-11-23	2023-04-01	美商阿尼拉製藥公司	絲胺酸蛋白酶抑制因子Ａ１ｉＲＮＡ組成物及其使用方法
US11033570B2 (en)	2016-12-02	2021-06-15	Cold Spring Harbor Laboratory	Modulation of Lnc05 expression
CN118546256A (zh)	2016-12-13	2024-08-27	西雅图儿童医院（Dba西雅图儿童研究所）	在体外和体内对工程化的细胞中表达的化学物质诱导的信号传导复合物进行外源性药物激活的方法
AU2017376950B2 (en)	2016-12-16	2024-02-22	Alnylam Pharmaceuticals, Inc.	Methods for treating or preventing TTR-associated diseases using transthyretin (TTR) iRNA compositions
SG11201906735RA (en)	2017-01-23	2019-08-27	Regeneron Pharma	Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
EP3585807A1 (de)	2017-02-22	2020-01-01	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung der parkinson-krankheit im frühstadium (park1) und anderer zustände oder störungen im zusammenhang mit dem synuclein-alpha (snca)-gen
US20200216857A1 (en)	2017-02-22	2020-07-09	Crispr Therapeutics Ag	Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
EP3585899A1 (de)	2017-02-22	2020-01-01	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von primärer hyperoxalurie typ 1 (ph1) und anderen mit dem alanin-glyoxylataminotransferase (agxt)-gen assoziierten erkrankungen oder störungen
EP3585898A1 (de)	2017-02-22	2020-01-01	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von spinozerebellärer ataxie typ 1 (sca1) und anderen mit dem gen des proteins von spinozerebellärer ataxie typ 1 (atxn1) assoziierten erkrankungen oder störungen
CN119351474A (zh)	2017-02-22	2025-01-24	克里斯珀医疗股份公司	用于基因编辑的组合物和方法
US11180756B2 (en)	2017-03-09	2021-11-23	Ionis Pharmaceuticals	Morpholino modified oligomeric compounds
WO2018183969A1 (en)	2017-03-30	2018-10-04	California Institute Of Technology	Barcoded rapid assay platform for efficient analysis of candidate molecules and methods of making and using the platform
WO2018191603A1 (en)	2017-04-14	2018-10-18	University Of Massachusetts	Targeting cell tropism receptors to inhibit cytomegalovirus infection
SG11201909572QA (en)	2017-04-18	2019-11-28	Alnylam Pharmaceuticals Inc	Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
CA3059321A1 (en)	2017-04-20	2018-10-25	Synthena Ag	Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
WO2018193428A1 (en)	2017-04-20	2018-10-25	Synthena Ag	Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
US12208140B2 (en)	2017-04-21	2025-01-28	The Broad Institute, Inc.	Targeted delivery to beta cells
BR112019023608A2 (pt)	2017-05-12	2020-05-26	Crispr Therapeutics Ag	Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
JP2020530442A (ja)	2017-07-10	2020-10-22	ジェンザイム・コーポレーション	血友病を有する対象の出血事象を処置するための方法および組成物
SG11202000167SA (en)	2017-07-11	2020-02-27	Synthorx Inc	Incorporation of unnatural nucleotides and methods thereof
JP2020526558A (ja)	2017-07-13	2020-08-31	ノースウェスタンユニバーシティ	オリゴヌクレオチド官能化金属有機構造体ナノ粒子を調製するための一般的かつ直接的な方法
CA3069868A1 (en)	2017-07-13	2019-01-17	Alnylam Pharmaceuticals Inc.	Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof
KR20250145137A (ko)	2017-08-03	2025-10-13	신톡스, 인크.	자가면역 질환의 치료를 위한 사이토카인 접합체
AU2018318231A1 (en)	2017-08-18	2020-02-13	Ionis Pharmaceuticals, Inc.	Modulation of the notch signaling pathway for treatment of respiratory disorders
CA3075205A1 (en)	2017-09-08	2019-03-14	Mina Therapeutics Limited	Stabilized hnf4a sarna compositions and methods of use
US10517889B2 (en)	2017-09-08	2019-12-31	Ionis Pharmaceuticals, Inc.	Modulators of SMAD7 expression
EP4219715A3 (de)	2017-09-08	2023-09-06	MiNA Therapeutics Limited	Stabilisierte cebpa-sarna-zusammensetzungen und verfahren zur verwendung
US11999953B2 (en)	2017-09-13	2024-06-04	The Children's Medical Center Corporation	Compositions and methods for treating transposon associated diseases
KR20200089656A (ko)	2017-09-19	2020-07-27	알닐람 파마슈티칼스 인코포레이티드	트랜스타이레틴(ttr) 매개 아밀로이드증을 치료하기 위한 조성물 및 방법
WO2019079527A1 (en)	2017-10-17	2019-04-25	Casebia Therapeutics Limited Liability Partnership	COMPOSITIONS AND METHODS FOR GENETIC EDITION FOR HEMOPHILIA A
EP3701029A1 (de)	2017-10-26	2020-09-02	Vertex Pharmaceuticals Incorporated	Materialien und verfahren zur behandlung von hämoglobinopathien
US11866701B2 (en)	2017-11-01	2024-01-09	Alnylam Pharmaceuticals, Inc.	Complement component C3 iRNA compositions and methods of use thereof
US20210032622A1 (en)	2017-11-09	2021-02-04	Crispr Therapeutics Ag	Self-inactivating (sin) crispr/cas or crispr/cpf1 systems and uses thereof
TWI809004B (zh)	2017-11-09	2023-07-21	美商Ionis製藥公司	用於降低snca表現之化合物及方法
US20200385719A1 (en)	2017-11-16	2020-12-10	Alnylam Pharmaceuticals, Inc.	Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
EP3714054A1 (de)	2017-11-20	2020-09-30	Alnylam Pharmaceuticals, Inc.	Serum-amyloid p-komponente (apcs) irna zusammensetzungen und verfahren zu deren verwendung
WO2019102381A1 (en)	2017-11-21	2019-05-31	Casebia Therapeutics Llp	Materials and methods for treatment of autosomal dominant retinitis pigmentosa
EP3714053B1 (de)	2017-11-22	2025-12-31	The University of Chicago	Von chemischer sonde abhängige bewertung der proteinaktivität und verwendung davon
SG11202005147WA (en)	2017-12-05	2020-06-29	Vertex Pharma	Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof
CN111801417B (zh)	2017-12-14	2024-10-29	克里斯珀医疗股份公司	新的rna-可编程的内切核酸酶系统及其在基因组编辑和其他应用中的用途
WO2019126097A1 (en)	2017-12-18	2019-06-27	Alnylam Pharmaceuticals, Inc.	High mobility group box-1 (hmgb1) irna compositions and methods of use thereof
EP3728595A1 (de)	2017-12-21	2020-10-28	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung des usher-syndroms des typs 2a und/oder von nichtsyndromaler autosomaler rezessiver retinitis pigmentosa (arrp)
EP3728594A1 (de)	2017-12-21	2020-10-28	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung des usher-syndroms typ 2a
WO2019126641A2 (en)	2017-12-21	2019-06-27	Ionis Pharmaceuticals, Inc.	Modulation of frataxin expression
IL275694B2 (en)	2017-12-29	2025-08-01	Scripps Research Inst	Unnatural base pair compositions and methods of use
US12178855B2 (en)	2018-01-10	2024-12-31	Translate Bio Ma, Inc.	Compositions and methods for facilitating delivery of synthetic nucleic acids to cells
WO2019140330A1 (en)	2018-01-12	2019-07-18	Casebia Therapeutics Limited Liability Partnership	Compositions and methods for gene editing by targeting transferrin
US20200392510A1 (en)	2018-01-15	2020-12-17	Ionis Pharmaceuticals, Inc.	Modulators of dnm2 expression
US12509492B2 (en)	2018-01-19	2025-12-30	Duke University	Genome engineering with CRISPR-Cas systems in eukaryotes
WO2019147743A1 (en)	2018-01-26	2019-08-01	Massachusetts Institute Of Technology	Structure-guided chemical modification of guide rna and its applications
US11268077B2 (en)	2018-02-05	2022-03-08	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of hemoglobinopathies
WO2019150196A1 (en)	2018-02-05	2019-08-08	Crispr Therapeutics Ag	Materials and methods for treatment of hemoglobinopathies
WO2019161310A1 (en)	2018-02-16	2019-08-22	Casebia Therapeutics Limited Liability Partnership	Compositions and methods for gene editing by targeting fibrinogen-alpha
WO2019165453A1 (en)	2018-02-26	2019-08-29	Synthorx, Inc.	Il-15 conjugates and uses thereof
TWI840345B (zh)	2018-03-02	2024-05-01	美商Ionis製藥公司	Irf4表現之調節劑
US11732260B2 (en)	2018-03-02	2023-08-22	Ionis Pharmaceuticals, Inc.	Compounds and methods for the modulation of amyloid-β precursor protein
JP7550648B2 (ja)	2018-03-19	2024-09-13	クリスパーセラピューティクスアーゲー	新規ｒｎａプログラム可能エンドヌクレアーゼ系およびその使用
EP3768694A4 (de)	2018-03-22	2021-12-29	Ionis Pharmaceuticals, Inc.	Verfahren zur modulierung der fmr1-expression
AU2019242912B2 (en)	2018-03-28	2025-07-17	Board Of Regents, The University Of Texas System	Identification of epigenetic alterations in DNA isolated from exosomes
WO2019186514A2 (en)	2018-03-30	2019-10-03	Rheinische Friedrich-Wilhelms-Universitat Bonn	Aptamers for targeted activaton of t cell-mediated immunity
CN116536272A (zh)	2018-04-06	2023-08-04	儿童医疗中心有限公司	用于体细胞重新编程和调整印记的组合物和方法
CA3094020A1 (en)	2018-04-11	2019-10-17	Ionis Pharmaceuticals, Inc.	Modulators of ezh2 expression
EP4242307A3 (de)	2018-04-12	2023-12-27	MiNA Therapeutics Limited	Sirt1-sarna kompositionen und methoden zu deren verwendung
WO2019204668A1 (en)	2018-04-18	2019-10-24	Casebia Therapeutics Limited Liability Partnership	Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
CA3091490A1 (en)	2018-04-27	2019-10-31	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Rapamycin resistant cells
EP3790970A1 (de)	2018-05-07	2021-03-17	Alnylam Pharmaceuticals Inc.	Extrahepatische verabreichung
SG11202010215TA (en)	2018-05-09	2020-11-27	Ionis Pharmaceuticals Inc	Compounds and methods for reducing atxn3 expression
JP7438135B2 (ja)	2018-05-09	2024-02-26	アイオーニスファーマシューティカルズ，インコーポレーテッド	Ｆｘｉの発現を低下させるための化合物及び方法
CA3099963A1 (en)	2018-05-11	2019-11-14	University Of Massachusetts	Methods for improving leptin sensitivity for the treatment of obesity and diabetes
TWI851574B (zh)	2018-05-14	2024-08-11	美商阿尼拉製藥公司	血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
US11833168B2 (en)	2018-06-14	2023-12-05	Ionis Pharmaceuticals, Inc.	Compounds and methods for increasing STMN2 expression
TWI833770B (zh)	2018-06-27	2024-03-01	美商Ionis製藥公司	用於減少 lrrk2 表現之化合物及方法
EP3823725A4 (de)	2018-07-17	2023-05-10	Aronora, Inc.	Verfahren zur sicheren reduzierung von thrombopoietin
CA3106986A1 (en)	2018-07-25	2020-01-30	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing atxn2 expression
MA70658B1 (fr)	2018-08-13	2026-04-30	Alnylam Pharmaceuticals, Inc.	Compositions d'agent d'arndb du virus de l'hépatite b (vhb) et leurs méthodes d'utilisation
US11987792B2 (en)	2018-08-16	2024-05-21	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the LECT2 gene
US12281308B2 (en)	2018-08-29	2025-04-22	University Of Massachusetts	Inhibition of protein kinases to treat Friedreich ataxia
CA3112793A1 (en)	2018-09-14	2020-03-19	Northwestern University	Programming protein polymerization with dna
WO2020060986A1 (en)	2018-09-18	2020-03-26	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (khk) irna compositions and methods of use thereof
WO2020068983A1 (en)	2018-09-25	2020-04-02	Co-Diagnostics, Inc.	Allele-specific design of cooperative primers for improved nucleic acid variant genotyping
JP7470107B2 (ja)	2018-09-28	2024-04-17	アルナイラムファーマシューティカルズ，インコーポレイテッド	トランスサイレチン（ＴＴＲ）ｉＲＮＡ組成物及びＴＴＲ関連眼疾患を治療又は予防するためのその使用方法
CA3116885A1 (en)	2018-10-17	2020-04-23	Crispr Therapeutics Ag	Compositions and methods for delivering transgenes
US10913951B2 (en)	2018-10-31	2021-02-09	University of Pittsburgh—of the Commonwealth System of Higher Education	Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
BR112021005401A2 (pt)	2018-11-08	2021-06-29	Synthorx, Inc.	conjugados de interleucina 10 e usos dos mesmos
TW202028222A (zh)	2018-11-14	2020-08-01	美商Ionis製藥公司	Foxp3表現之調節劑
EA202191342A1 (ru)	2018-11-15	2021-08-10	Айонис Фармасьютикалз, Инк.	Модуляторы экспрессии irf5
US12281305B2 (en)	2018-11-21	2025-04-22	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing prion expression
CA3121191A1 (en)	2018-11-28	2020-06-04	Crispr Therapeutics Ag	Optimized mrna encoding cas9 for use in lnps
WO2020117706A1 (en)	2018-12-03	2020-06-11	Triplet Therapeutics, Inc.	Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh3 activity
WO2020118259A1 (en)	2018-12-06	2020-06-11	Northwestern University	Protein crystal engineering through dna hybridization interactions
CN113631709A (zh)	2018-12-20	2021-11-09	普拉克西斯精密药物股份有限公司	用于治疗kcnt1相关病症的组合物和方法
LT4285929T (lt)	2018-12-20	2026-01-12	Humabs Biomed Sa	Kompleksinė hbv terapija
CN113557023A (zh)	2019-01-16	2021-10-26	建新公司	Serpinc1 iRNA组合物及其使用方法
MX2021008918A (es)	2019-01-31	2021-08-24	Ionis Pharmaceuticals Inc	Moduladores de expresion yap1.
US20200246467A1 (en)	2019-02-06	2020-08-06	Synthorx, Inc.	Il-2 conjugates and methods of use thereof
EP3923992A1 (de)	2019-02-15	2021-12-22	CRISPR Therapeutics AG	Geneditierung für hämophilie a mit verbesserter faktor-viii-expression
WO2020171889A1 (en)	2019-02-19	2020-08-27	University Of Rochester	Blocking lipid accumulation or inflammation in thyroid eye disease
WO2020176771A1 (en)	2019-02-27	2020-09-03	Ionis Pharmaceuticals, Inc.	Modulators of malat1 expression
US20220145274A1 (en)	2019-03-12	2022-05-12	Crispr Therapeutics Ag	Novel high fidelity rna-programmable endonuclease systems and uses thereof
WO2020191177A1 (en)	2019-03-21	2020-09-24	Sudhir Agrawal	Antisense oligonucleotides for allele specificity
BR112021018793A2 (pt)	2019-03-29	2021-11-23	Mitsubishi Tanabe Pharma Corp	Oligonucleotídeo modificado, composição farmacêutica compreendendo o mesmo composto para modular a expressão de dux4 e uso
CA3135180A1 (en)	2019-03-29	2020-10-08	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating ube3a-ats
WO2020208361A1 (en)	2019-04-12	2020-10-15	Mina Therapeutics Limited	Sirt1-sarna compositions and methods of use
TWI902693B (zh)	2019-05-13	2025-11-01	美商維爾生物科技公司	用於治療ｂ型肝炎病毒（ｈｂｖ）感染之組成物及方法
US20220211743A1 (en)	2019-05-17	2022-07-07	Alnylam Pharmaceuticals, Inc.	Oral delivery of oligonucleotides
BR112021025130A2 (pt)	2019-06-14	2022-03-15	Scripps Research Inst	Reagentes e métodos para replicação, transcrição e tradução em organismos semissintéticos
ES3048358T3 (en)	2019-07-26	2025-12-10	Ionis Pharmaceuticals Inc	Compounds and methods for modulating gfap
EP4007812A1 (de)	2019-08-01	2022-06-08	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen der serpinfamilie f element 2 (serpinf2) und verfahren zu deren verwendung
EP4007811A2 (de)	2019-08-01	2022-06-08	Alnylam Pharmaceuticals, Inc.	Carboxypeptidase-b2(cpb2)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2021030522A1 (en)	2019-08-13	2021-02-18	Alnylam Pharmaceuticals, Inc.	SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
TW202543680A (zh)	2019-08-15	2025-11-16	美商欣爍克斯公司	使用il-2接合物之免疫腫瘤學組合療法
KR20220062517A (ko)	2019-08-15	2022-05-17	아이오니스 파마수티컬즈, 인코포레이티드	결합 변형된 올리고머 화합물 및 이의 용도
EP4017539A1 (de)	2019-08-19	2022-06-29	MiNA Therapeutics Limited	Oligonukleotidkonjugatzusammensetzungen und verwendungsverfahren
PH12022500004A1 (en)	2019-08-23	2023-04-03	Synthorx Inc	Il-15 conjugates and uses thereof
US20220290152A1 (en)	2019-09-03	2022-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
MX2022002740A (es)	2019-09-10	2022-03-25	Synthorx Inc	Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
US12319711B2 (en)	2019-09-20	2025-06-03	Northwestern University	Spherical nucleic acids with tailored and active protein coronae
WO2021067747A1 (en)	2019-10-04	2021-04-08	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing ugt1a1 gene expression
WO2021076828A1 (en)	2019-10-18	2021-04-22	Alnylam Pharmaceuticals, Inc.	Solute carrier family member irna compositions and methods of use thereof
BR112022007540A2 (pt)	2019-10-22	2022-07-12	Alnylam Pharmaceuticals Inc	Composições de irna de componente complementar c3 e métodos de uso das mesmas
US12378560B2 (en)	2019-10-29	2025-08-05	Northwestern University	Sequence multiplicity within spherical nucleic acids
WO2021087325A1 (en)	2019-11-01	2021-05-06	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing dnajb1-prkaca fusion gene expression
CN114728018B (zh)	2019-11-01	2024-07-19	阿尔尼拉姆医药品有限公司	亨廷顿(HTT)iRNA药剂组合物及其使用方法
AU2020380275A1 (en)	2019-11-04	2022-04-14	Synthorx, Inc.	Interleukin 10 conjugates and uses thereof
EP4055165A1 (de)	2019-11-06	2022-09-14	Alnylam Pharmaceuticals, Inc.	Transthyretin (ttr)-irna-zusammensetzungen und verfahren zur verwendung davon für die behandlung oder prävention ttr-assoziierter augenerkrankungen
AU2020378414A1 (en)	2019-11-06	2022-05-26	Alnylam Pharmaceuticals, Inc.	Extrahepatic delivery
TW202526019A (zh)	2019-11-13	2025-07-01	美商阿尼拉製藥公司	用於治療血管收縮素原相關病症之方法及組成物
EP4061945A1 (de)	2019-11-22	2022-09-28	Alnylam Pharmaceuticals, Inc.	Ataxin3 (atxn3)-rnai-wirkstoffzusammensetzungen und verfahren zu deren verwendung
TWI897902B (zh)	2019-12-13	2025-09-21	美商阿尼拉製藥公司	人類染色體9開讀框72 (C9ORF72) iRNA劑組成物及其使用方法
WO2021126734A1 (en)	2019-12-16	2021-06-24	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
EP4077674A1 (de)	2019-12-18	2022-10-26	Alia Therapeutics S.R.L.	Zusammensetzungen und verfahren zur behandlung von retinitis pigmentosa
EP4706689A2 (de)	2019-12-19	2026-03-11	Entrada Therapeutics, Inc.	Zusammensetzungen zur verabreichung von antisense-verbindungen
US12503695B2 (en)	2020-01-27	2025-12-23	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	RAB13 and NET1 antisense oligonucleotides to treat metastatic cancer
WO2021154941A1 (en)	2020-01-31	2021-08-05	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
MX2022009763A (es)	2020-02-10	2022-09-09	Alnylam Pharmaceuticals Inc	Composiciones y metodos para silenciar la expresion del factor de crecimiento endotelial vascular a (vegf-a).
WO2021167841A1 (en)	2020-02-18	2021-08-26	Alnylam Pharmaceuticals, Inc.	Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
PH12022552258A1 (en)	2020-02-28	2023-11-20	Ionis Pharmaceuticals Inc	Compounds and methods for modulating smn2
GB2627644B (en)	2020-03-04	2024-11-20	Verve Therapeutics Inc	Method for the preparation of GalNAc-lipid nanoparticle
EP4114947A1 (de)	2020-03-05	2023-01-11	Alnylam Pharmaceuticals, Inc.	Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
WO2021178736A1 (en)	2020-03-06	2021-09-10	Alnylam Pharmaceuticals, Inc.	KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
JP7802676B2 (ja)	2020-03-06	2026-01-20	アルナイラムファーマシューティカルズ，インコーポレイテッド	トランスサイレチン（ｔｔｒ）の発現を阻害するための組成物および方法
EP4121534A1 (de)	2020-03-18	2023-01-25	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt)
WO2021195307A1 (en)	2020-03-26	2021-09-30	Alnylam Pharmaceuticals, Inc.	Coronavirus irna compositions and methods of use thereof
EP4127171A2 (de)	2020-03-30	2023-02-08	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur ausschaltung der dnajc15-genexpression
US12534731B2 (en)	2020-04-01	2026-01-27	Alnylam Pharmaceuticals, Inc.	Alpha-2A adrenergic receptor (ADRA2A) iRNA agent compositions and methods of use thereof
CA3179411A1 (en)	2020-04-06	2021-10-14	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing myoc expression
WO2021206917A1 (en)	2020-04-07	2021-10-14	Alnylam Pharmaceuticals, Inc.	ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
IL297130A (en)	2020-04-07	2022-12-01	Alnylam Pharmaceuticals Inc	Compositions and methods for silencing scn9a expression
WO2021206922A1 (en)	2020-04-07	2021-10-14	Alnylam Pharmaceuticals, Inc.	Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
WO2021222065A1 (en)	2020-04-27	2021-11-04	Alnylam Pharmaceuticals, Inc.	Apolipoprotein e (apoe) irna agent compositions and methods of use thereof
EP4142738A1 (de)	2020-04-30	2023-03-08	Alnylam Pharmaceuticals, Inc.	Komplementfaktor-b (cfb)-irna-zusammensetzungen und verfahren zur verwendung davon
KR20230005933A (ko)	2020-05-01	2023-01-10	아이오니스 파마수티컬즈, 인코포레이티드	Atxn1을 조정하는 화합물 및 방법
CN115667513A (zh)	2020-05-12	2023-01-31	田边三菱制药株式会社	用于调节Ataxin 3表达的化合物、方法和药物组合物
WO2021231698A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
WO2021231692A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of otoferlin (otof)
WO2021231673A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
WO2021231691A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
EP4150077A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von transmembrankanalähnlichem protein 1 (tmc1)
EP4150088A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von argininosuccinat-synthetase (ass1)
WO2021231679A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
WO2021231680A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
EP4153746A1 (de)	2020-05-21	2023-03-29	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der marc1-genexpression
JP2023526533A (ja)	2020-05-22	2023-06-21	ウェイブライフサイエンシズリミテッド	二本鎖オリゴヌクレオチド組成物及びそれに関連する方法
US11408000B2 (en)	2020-06-03	2022-08-09	Triplet Therapeutics, Inc.	Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
EP4161552A1 (de)	2020-06-05	2023-04-12	The Broad Institute, Inc.	Zusammensetzungen und verfahren zur behandlung von neoplasien
EP4162050A1 (de)	2020-06-09	2023-04-12	Alnylam Pharmaceuticals, Inc.	Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation
US20230203496A1 (en)	2020-06-09	2023-06-29	Alnylam Pharmaceuticals, Inc.	Sirna compositions and methods for silencing gpam (glycerol-3-phosphate acyltransferase 1, mitochondrial) expression
AU2021292296A1 (en)	2020-06-18	2023-01-19	Alnylam Pharmaceuticals, Inc.	Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof
AR122722A1 (es)	2020-06-24	2022-09-28	Vir Biotechnology Inc	Anticuerpos que neutralizan el virus de la hepatitis b y sus usos
JP2023531509A (ja)	2020-06-25	2023-07-24	シンソークス，インコーポレイテッド	Ｉｌ－２コンジュゲートおよび抗ｅｇｆｒ抗体を用いる免疫腫瘍学併用療法
IL298530A (en)	2020-06-29	2023-01-01	Ionis Pharmaceuticals Inc	Compounds and methods for modulating plp1
IL299771A (en)	2020-07-10	2023-03-01	Inst Nat Sante Rech Med	Methods and compounds for the treatment of epilepsy
WO2022011214A1 (en)	2020-07-10	2022-01-13	Alnylam Pharmaceuticals, Inc.	Circular sirnas
KR20230043914A (ko)	2020-07-28	2023-03-31	아이오니스 파마수티컬즈, 인코포레이티드	App 발현을 감소시키기 위한 화합물 및 방법
TW202221123A (zh)	2020-08-07	2022-06-01	美商Ionis製藥公司	調節ｓｃｎ２ａ之化合物及方法
EP4208549A4 (de)	2020-09-04	2025-04-16	Verve Therapeutics, Inc.	Zusammensetzungen und verfahren zum capping von rnas
EP4217489A1 (de)	2020-09-24	2023-08-02	Alnylam Pharmaceuticals, Inc.	Dipeptidylpeptidase 4 (dpp4)-irna-zusammensetzungen und verfahren zur verwendung davon
EP4222264A1 (de)	2020-09-30	2023-08-09	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von amyotropher lateralsklerose
TW202229552A (zh)	2020-10-05	2022-08-01	美商艾拉倫製藥股份有限公司	Ｇ蛋白－偶合受體７５（ＧＰＲ７５）ｉＲＮＡ組成物及其使用方法
EP3978608A1 (de)	2020-10-05	2022-04-06	SQY Therapeutics	Oligomere verbindung zur dystrophinrettung in dmd-patienten während des skipping exon-51
JP2023546010A (ja)	2020-10-09	2023-11-01	シンソークス，インコーポレイテッド	Ｉｌ－２コンジュゲートを用いた免疫腫瘍療法
IL301611A (en)	2020-10-09	2023-05-01	Synthorx Inc	Immuno oncology combination therapy with il-2 conjugates and pembrolizumab
AU2021365822A1 (en)	2020-10-21	2023-06-08	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating primary hyperoxaluria
CN116761885A (zh)	2020-10-23	2023-09-15	斯克利普斯研究所	包含非天然核苷酸的多核苷酸的逆转录
WO2022087329A1 (en)	2020-10-23	2022-04-28	Alnylam Pharmaceuticals, Inc.	Mucin 5b (muc5b) irna compositions and methods of use thereof
WO2022103999A1 (en)	2020-11-13	2022-05-19	Alnylam Pharmaceuticals, Inc.	COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
JP7820374B2 (ja)	2020-11-18	2026-02-25	アイオーニスファーマシューティカルズ，インコーポレーテッド	アンジオテンシノーゲン発現を調節するための化合物及び方法
EP4256053A1 (de)	2020-12-01	2023-10-11	Alnylam Pharmaceuticals, Inc.	Verfahren und zusammensetzungen zur hemmung der hao1 (hydroxysäureoxidase 1 (glycolatoxidase))-genexpression
WO2022125490A1 (en)	2020-12-08	2022-06-16	Alnylam Pharmaceuticals, Inc.	Coagulation factor x (f10) irna compositions and methods of use thereof
US12018261B2 (en)	2020-12-18	2024-06-25	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating factor XII
BR112023012377A2 (pt)	2020-12-23	2023-10-24	Flagship Pioneering Innovations Vi Llc	Composições de trems modificadas e usos das mesmas
EP4271695A2 (de)	2020-12-31	2023-11-08	Alnylam Pharmaceuticals, Inc.	Auf 2'-modifiziertem nukleosid basierende oligonukleotid-prodrugs
WO2022147214A2 (en)	2020-12-31	2022-07-07	Alnylam Pharmaceuticals, Inc.	Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
EP4274896A1 (de)	2021-01-05	2023-11-15	Alnylam Pharmaceuticals, Inc.	Komplementkomponente 9 (c9)-irna-zusammensetzungen und verfahren zur verwendung davon
TW202302148A (zh)	2021-02-12	2023-01-16	美商欣爍克斯公司	使用ｉｌ－２接合物和抗ｐｄ－１抗體或其抗原結合片段的肺癌組合療法
TW202245843A (zh)	2021-02-12	2022-12-01	美商欣爍克斯公司	Ｉｌ－２接合物及西米普利單抗（ｃｅｍｉｐｌｉｍａｂ）之皮膚癌組合療法
EP4291654A2 (de)	2021-02-12	2023-12-20	Alnylam Pharmaceuticals, Inc.	Superoxid-dismutase-1 (sod1)-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder vorbeugung von mit superoxid-dismutase 1 (sod1-) assoziierten neurodegenerativen erkrankungen
WO2022182864A1 (en)	2021-02-25	2022-09-01	Alnylam Pharmaceuticals, Inc.	Prion protein (prnp) irna compositions and methods and methods of use thereof
JP2024515423A (ja)	2021-02-26	2024-04-10	アルナイラムファーマシューティカルズ，インコーポレイテッド	ケトヘキソキナーゼ（ＫＨＫ）ｉＲＮＡ組成物およびその使用方法
AU2022231003A1 (en)	2021-03-04	2023-09-14	Alnylam Pharmaceuticals, Inc.	Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
EP4305169A1 (de)	2021-03-12	2024-01-17	Alnylam Pharmaceuticals, Inc.	Glykogensynthasekinase-3-alpha (gsk3a)-irna-zusammensetzungen und verfahren zur verwendung davon
US20220288181A1 (en)	2021-03-12	2022-09-15	Northwestern University	Antiviral vaccines using spherical nucleic acids
CA3214137A1 (en)	2021-03-26	2022-09-29	Mina Therapeutics Limited	Tmem173 sarna compositions and methods of use
IL307239A (en)	2021-03-29	2023-11-01	Alnylam Pharmaceuticals Inc	Preparations containing Huntingtin IRNA factor (HTT) and methods of using them
US20250243244A1 (en)	2021-03-31	2025-07-31	Entrada Therapeutics, Inc.	Cyclic cell penetrating peptides
WO2022212153A1 (en)	2021-04-01	2022-10-06	Alnylam Pharmaceuticals, Inc.	Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
CA3214540A1 (en)	2021-04-22	2022-10-27	Pasi A. Janne	Compositions and methods for treating cancer
BR112023022284A2 (pt)	2021-04-26	2023-12-26	Alnylam Pharmaceuticals Inc	Composições de irna de protease transmembrana, serina 6 (tmprss6) e métodos de uso da mesma
EP4330396A1 (de)	2021-04-29	2024-03-06	Alnylam Pharmaceuticals, Inc.	Signalwandler und aktivator von transkriptionsfaktor 6 (stat6)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2022235537A1 (en)	2021-05-03	2022-11-10	Alnylam Pharmaceuticals, Inc.	Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
WO2022240721A1 (en)	2021-05-10	2022-11-17	Entrada Therapeutics, Inc.	Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
AU2022271873A1 (en)	2021-05-10	2024-01-04	Entrada Therapeutics, Inc.	Compositions and methods for intracellular therapeutics
EP4337261A2 (de)	2021-05-10	2024-03-20	Entrada Therapeutics, Inc.	Zusammensetzungen und verfahren zur modulation des spleissens von mrna
EP4341401A1 (de)	2021-05-18	2024-03-27	Alnylam Pharmaceuticals, Inc.	Natriumglucose-cotransporter-2-(sglt2)-irna-zusammensetzungen und verfahren zur verwendung davon
EP4341405A1 (de)	2021-05-20	2024-03-27	Korro Bio, Inc.	Verfahren und zusammensetzungen für adar-vermittelte bearbeitung
WO2022256283A2 (en)	2021-06-01	2022-12-08	Korro Bio, Inc.	Methods for restoring protein function using adar
JP2024522996A (ja)	2021-06-02	2024-06-25	アルナイラムファーマシューティカルズ，インコーポレイテッド	パタチン様ホスホリパーゼドメイン含有３（ＰＮＰＬＡ３）ｉＲＮＡ組成物およびその使用方法
TW202313679A (zh)	2021-06-03	2023-04-01	美商欣爍克斯公司	包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法
BR112023025224A2 (pt)	2021-06-04	2024-02-27	Alnylam Pharmaceuticals Inc	Quadro de leitura aberto 72 do cromossomo humano 9 (c9orf72) composições de agente de irna e métodos de uso dos mesmos
EP4351541A2 (de)	2021-06-08	2024-04-17	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur behandlung oder prävention von erkrankungen im zusammenhang mit morbus stargardt und/oder retinal-bindendem protein 4 (rbp4)
EP4101928A1 (de)	2021-06-11	2022-12-14	Bayer AG	Programmierbare typ-v-rna-endonukleasesysteme
IL308896A (en)	2021-06-11	2024-01-01	Bayer Ag	Type v rna programmable endonuclease systems
EP4355759A4 (de)	2021-06-18	2026-05-13	Ionis Pharmaceuticals Inc	Verbindungen und verfahren zur reduzierung der ifnar1-expression
GEAP202416440A (en)	2021-06-23	2024-04-25	Entrada Therapeutics Inc	Antisense compounds and methods for targeting cug repeats
US20250034564A1 (en)	2021-06-29	2025-01-30	Korro Bio, Inc.	Methods and Compositions for ADAR-Mediated Editing
US20230194709A9 (en)	2021-06-29	2023-06-22	Seagate Technology Llc	Range information detection using coherent pulse sets with selected waveform characteristics
MX2023015489A (es)	2021-06-30	2024-01-19	Alnylam Pharmaceuticals Inc	Metodos y composiciones para tratar un trastorno asociado al angiotensinogeno (agt).
WO2023283403A2 (en)	2021-07-09	2023-01-12	Alnylam Pharmaceuticals, Inc.	Bis-rnai compounds for cns delivery
WO2023285431A1 (en)	2021-07-12	2023-01-19	Alia Therapeutics Srl	Compositions and methods for allele specific treatment of retinitis pigmentosa
WO2023003805A1 (en)	2021-07-19	2023-01-26	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
KR20240036041A (ko)	2021-07-21	2024-03-19	알닐람 파마슈티칼스 인코포레이티드	대사 장애-연관 표적 유전자 iRNA 조성물 및 이의 사용 방법
JP2024528701A (ja)	2021-07-23	2024-07-30	アルナイラムファーマシューティカルズ，インコーポレイテッド	ベータカテニン（ＣＴＮＮＢ１）ｉＲＮＡ組成物およびその使用方法
JP2024529437A (ja)	2021-07-29	2024-08-06	アルナイラムファーマシューティカルズ，インコーポレイテッド	３－ヒドロキシ－３－メチルグリタル－ＣＯＡレダクターゼ（ＨＭＧＣＲ）ｉＲＮＡ組成物およびその使用方法
EP4380576A4 (de)	2021-08-03	2026-04-29	Verve Therapeutics Inc	Zusammensetzungen und verfahren zur gezielten rna-abgabe
TW202328445A (zh)	2021-08-03	2023-07-16	美商艾拉倫製藥股份有限公司	甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物及其使用方法
PE20241132A1 (es)	2021-08-04	2024-05-24	Alnylam Pharmaceuticals Inc	Composiciones de arni y metodos para silenciar el angiotensinogeno (agt)
IL310407A (en)	2021-08-13	2024-03-01	Alnylam Pharmaceuticals Inc	Factor XII (F12) IRNA compositions and methods of using them
MX2024002440A (es)	2021-08-31	2024-03-08	Alnylam Pharmaceuticals Inc	Composiciones de acido ribonucleico de interferencia (arni) del efector b similar al factor de fragmentacion de adn subunidad alfa (dffa) que induce la muerte celular (cideb) y metodos de uso de estas.
EP4395829A1 (de)	2021-09-01	2024-07-10	Entrada Therapeutics, Inc.	Verbindungen und verfahren zum überspringen von exon 44 bei duchenne-muskeldystrophie
EP4144841A1 (de)	2021-09-07	2023-03-08	Bayer AG	Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
JP2024535850A (ja)	2021-09-17	2024-10-02	アルナイラムファーマシューティカルズ，インコーポレイテッド	補体成分（Ｃ３）をサイレンシングするためのｉＲＮＡ組成物および方法
EP4405478A1 (de)	2021-09-20	2024-07-31	Alnylam Pharmaceuticals, Inc.	Inhibinuntereinheits-beta-e (inhbe)-modulatorzusammensetzungen und verfahren zur verwendung davon
MX2024003519A (es)	2021-09-24	2024-04-01	Alnylam Pharmaceuticals Inc	Composiciones de agentes de acido ribonucleico de interferencia (arni) de proteina tau asociada a microtubulos (mapt) y sus metodos de uso.
CA3233755A1 (en)	2021-10-01	2023-04-06	Adarx Pharmaceuticals, Inc.	Prekallikrein-modulating compositions and methods of use thereof
IL311864A (en)	2021-10-15	2024-06-01	Alnylam Pharmaceuticals Inc	IRNA compositions for extrahepatic administration and methods of using them
AU2022370009A1 (en)	2021-10-22	2024-05-16	Korro Bio, Inc.	Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
TW202334418A (zh)	2021-10-29	2023-09-01	美商艾拉倫製藥股份有限公司	杭丁頓（ＨＴＴ）ｉＲＮＡ劑組成物及其使用方法
CA3234636A1 (en)	2021-10-29	2023-05-04	Alnylam Pharmaceuticals, Inc.	Complement factor b (cfb) irna compositions and methods of use thereof
US20240200078A1 (en)	2021-11-18	2024-06-20	Cornell University	Microrna-dependent mrna switches for tissue-specific mrna-based therapies
WO2023099884A1 (en)	2021-12-01	2023-06-08	Mina Therapeutics Limited	Pax6 sarna compositions and methods of use
WO2023122573A1 (en)	2021-12-20	2023-06-29	Synthorx, Inc.	Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
CA3243006A1 (en)	2021-12-21	2025-02-27	Alia Therapeutics Srl	TYPE II CAS PROTEINS AND THEIR APPLICATIONS
CA3243301A1 (en)	2021-12-23	2023-06-29	Bayer Aktiengesellschaft	NEW SMALL PROGRAMMABLE TYPE V RNA ENDONUCLEASE SYSTEMS
WO2023122750A1 (en)	2021-12-23	2023-06-29	Synthorx, Inc.	Cancer combination therapy with il-2 conjugates and cetuximab
EP4469575A2 (de)	2022-01-24	2024-12-04	Alnylam Pharmaceuticals, Inc.	Enzym-irna-wirkstoffzusammensetzungen für den heparinsulfatbiosyntheseweg und verfahren zur verwendung davon
US12037616B2 (en)	2022-03-01	2024-07-16	Crispr Therapeutics Ag	Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions
WO2023170435A1 (en)	2022-03-07	2023-09-14	Mina Therapeutics Limited	Il10 sarna compositions and methods of use
WO2023194359A1 (en)	2022-04-04	2023-10-12	Alia Therapeutics Srl	Compositions and methods for treatment of usher syndrome type 2a
JP2025516680A (ja)	2022-05-13	2025-05-30	アルナイラムファーマシューティカルズ，インコーポレイテッド	一本鎖ループオリゴヌクレオチド
WO2023237587A1 (en)	2022-06-10	2023-12-14	Bayer Aktiengesellschaft	Novel small type v rna programmable endonuclease systems
EP4547683A2 (de)	2022-06-30	2025-05-07	Alnylam Pharmaceuticals, Inc.	Oligonukleotid-prodrugs auf basis von mit cyclischem disulfid modifiziertem phosphat
JP2025527531A (ja)	2022-08-18	2025-08-22	アルナイラムファーマシューティカルズ，インコーポレイテッド	ユニバーサル非標的ｓｉｒｎａ組成物およびその使用方法
TW202424193A (zh)	2022-09-15	2024-06-16	美商艾拉倫製藥股份有限公司	第１３型１７β－羥基類固醇去氫酶（ＨＳＤ１７Ｂ１３）ｉＲＮＡ組成物及其使用方法
CA3267752A1 (en)	2022-09-16	2024-03-21	Alia Therapeutics Srl	ENQP TYPE II CAS PROTEINS AND THEIR APPLICATIONS
CN120239607A (zh)	2022-09-23	2025-07-01	Ionis制药公司	用于降低mecp2表达的化合物和方法
JP2025532985A (ja)	2022-09-30	2025-10-03	アルナイラムファーマシューティカルズ，インコーポレイテッド	修飾二本鎖ｒｎａ剤
WO2024105162A1 (en)	2022-11-16	2024-05-23	Alia Therapeutics Srl	Type ii cas proteins and applications thereof
EP4634376A2 (de)	2022-12-13	2025-10-22	Bayer Aktiengesellschaft	Gentechnisch hergestellte typ-v-rna-programmierbare endonukleasen und deren verwendungen
WO2024136899A1 (en)	2022-12-21	2024-06-27	Synthorx, Inc.	Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
WO2024134199A1 (en)	2022-12-22	2024-06-27	Mina Therapeutics Limited	Chemically modified sarna compositions and methods of use
JP2026502531A (ja)	2023-01-11	2026-01-23	アリアセラピューティクスエスアールエル	Ｉｉ型ｃａｓタンパク質およびその適用
AU2024217843A1 (en)	2023-02-09	2025-07-31	Alnylam Pharmaceuticals, Inc.	Reversir molecules and methods of use thereof
WO2024170778A1 (en)	2023-02-17	2024-08-22	Anjarium Biosciences Ag	Methods of making dna molecules and compositions and uses thereof
TW202444349A (zh)	2023-03-20	2024-11-16	美商欣爍克斯公司	使用ｉｌ－２綴合物之癌症療法
UY40699A (es)	2023-04-05	2024-08-30	Ionis Pharmaceuticals Inc	Compuestos y métodos para reducir la expresión de pln
CN121816199A (zh)	2023-04-12	2026-04-07	阿尔尼拉姆制药公司	双链rna药剂的肝外递送
CN121285630A (zh)	2023-04-20	2026-01-06	阿达尔克斯制药有限公司	Mapt调节组合物及其使用方法
WO2024220746A2 (en)	2023-04-21	2024-10-24	Flagship Pioneering Innovations Vii, Llc	Rnai agents targeting fatty acid synthase and related methods
WO2024226499A1 (en)	2023-04-24	2024-10-31	The Broad Institute, Inc.	Compositions and methods for modifying fertility
KR20260021635A (ko)	2023-05-12	2026-02-13	아다르엑스 파마슈티컬스, 인크.	Nmda 리간드 접합 화합물 및 이의 용도
CN121729491A (zh)	2023-05-12	2026-03-24	阿尔尼拉姆制药公司	单链环寡核苷酸
IL324720A (en)	2023-05-26	2026-01-01	Adarx Pharmaceuticals Inc	SOD1 modulators and methods of using them
CN121712891A (zh)	2023-06-20	2026-03-20	阿达尔克斯制药有限公司	Lrrk2调节组合物及其使用方法
WO2025003344A1 (en)	2023-06-28	2025-01-02	Alia Therapeutics Srl	Type ii cas proteins and applications thereof
WO2025015338A1 (en)	2023-07-13	2025-01-16	Korro Bio, Inc.	Rna-editing oligonucleotides and uses thereof
AU2024287308A1 (en)	2023-07-13	2025-12-18	Korro Bio, Inc.	Rna-editing oligonucleotides and uses thereof
KR20260044219A (ko)	2023-07-21	2026-04-01	매로우 테라퓨틱스, 인크.	조혈 세포 표적화 접합체 및 관련 방법
IL326321A (en)	2023-08-04	2026-04-01	Alnylam Pharmaceuticals Inc	Methods and compositions for treating CTNNB1-related disorders
IL327100A (en)	2023-09-15	2026-05-01	Praxis Prec Medicines Inc	Alsonarsen/PRAX-22 for use in the treatment of SCN2A-related disorders
IL326940A (en)	2023-09-21	2026-05-01	Alnylam Pharmaceuticals Inc	Activin A Receptor Type 1C (ACVR1C) IRNA Compositions and Methods of Using Them
WO2025072713A1 (en)	2023-09-27	2025-04-03	Judo Bio, Inc.	Polymyxins for delivery of agents to the kidney
WO2025072672A2 (en)	2023-09-27	2025-04-03	Judo Bio, Inc.	Slc6a19-targeting modulatory nucleic acid agents
AU2024348221A1 (en)	2023-09-27	2026-04-30	Judo Bio Inc.	Aminoglycosides for delivery of agents to the kidney
WO2025076031A2 (en)	2023-10-03	2025-04-10	Alnylam Pharmaceuticals, Inc.	Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof
CN121969744A (zh)	2023-10-06	2026-05-01	拜耳公司	工程化v型rna可编程核酸内切酶及其用途
WO2025096809A1 (en)	2023-10-31	2025-05-08	Korro Bio, Inc.	Oligonucleotides comprising phosphoramidate internucleotide linkages
WO2025128799A1 (en)	2023-12-12	2025-06-19	Korro Bio, Inc.	Double-stranded rna-editing oligonucleotides and uses thereof
WO2025158385A1 (en)	2024-01-25	2025-07-31	Genzyme Corporation	Pegylated il-2 for suppressing adaptive immune response to gene therapy
WO2025178854A2 (en)	2024-02-19	2025-08-28	Flagship Pioneering Innovations Vii, Llc	Rnai agents targeting cideb and related methods
WO2025199231A2 (en)	2024-03-20	2025-09-25	Vertex Pharmaceuticals Incorporated	Mucin-5b (muc5b) targeted sirna and antisense oligonucleotides and methods of use thereof
WO2025207517A2 (en)	2024-03-25	2025-10-02	Synthorx, Inc.	Synthetic trna synthetases and cells comprising synthetic molecules for production of polypeptides
WO2025210147A1 (en)	2024-04-04	2025-10-09	Alia Therapeutics Srl	Type v cas proteins and applications thereof
WO2025217275A2 (en)	2024-04-10	2025-10-16	Flagship Pioneering Innovations Vii, Llc	Immune cell targeted compositions and related methods
WO2025259747A2 (en)	2024-06-12	2025-12-18	Alnylam Pharmaceuticals, Inc.	Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof
WO2025259743A1 (en)	2024-06-12	2025-12-18	Alnylam Pharmaceuticals, Inc.	Dual conjugate compounds for extrahepatic delivery
WO2026006436A1 (en)	2024-06-25	2026-01-02	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of tar dna binding protein 43 kda (tdp43)
WO2026027887A2 (en)	2024-08-02	2026-02-05	Mina Therapeutics Limited	Hbg1/2-sarna compositions and methods of use
WO2026050243A1 (en)	2024-08-26	2026-03-05	Korro Bio, Inc.	Galnac conjugated oligonucleotides for rna editing
WO2026055461A1 (en)	2024-09-05	2026-03-12	Aperture Therapeutics, Inc.	Antibody oligonucleotide conjugates comprising an antisense polynucleotide agent conjugated to a cd33 antibody and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4470954A (en) *	1983-06-13	1984-09-11	Chiknas Steven G	Rotor or carrier for centrifugal analyzer and bead washer
DD238395A1 (de) *	1985-06-19	1986-08-20	Akad Wissenschaften Ddr	Verfahren zur selektiven fixierung von biologisch aktiven stoffen
US4806546A (en) *	1985-09-30	1989-02-21	Miles Inc.	Immobilization of nucleic acids on derivatized nylon supports
JPS62197425A (ja) *	1986-02-25	1987-09-01	Toyo Soda Mfg Co Ltd	球状熱可塑性樹脂の製造方法
GB2197720A (en) *	1986-11-20	1988-05-25	Nat Res Dev	Immobilisation of polynucleotides
AU1363688A (en) *	1987-02-12	1988-09-14	Sdi Diagnostics, Inc.	Test system, test device and method for detecting pathogenic organisms and antibiotic resistance genes in body fluids
IL85551A0 (en) *	1987-04-01	1988-08-31	Miles Inc	Rapid hybridization assay and reagent system used therein
US4921805A (en) *	1987-07-29	1990-05-01	Life Technologies, Inc.	Nucleic acid capture method
US4921788A (en) *	1988-04-12	1990-05-01	The Research Foundation Of State University Of New York	Competitive nucleic acid immunoassay for the detection of analytes
IE904365A1 (en) *	1990-02-13	1991-08-14	Epitope	Stick probe device for detection of antibodies

1990
- 1990-09-04 AT AT90309671T patent/ATE167523T1/de not_active IP Right Cessation
- 1990-09-04 EP EP90309671A patent/EP0455905B1/de not_active Expired - Lifetime
- 1990-09-04 EP EP96113623A patent/EP0745689A3/de not_active Withdrawn
- 1990-09-04 DK DK90309671T patent/DK0455905T3/da active
- 1990-09-04 DE DE69032425T patent/DE69032425T2/de not_active Expired - Lifetime
- 1990-09-04 ES ES90309671T patent/ES2116977T3/es not_active Expired - Lifetime
- 1990-09-17 JP JP2244155A patent/JPH0420300A/ja active Pending
1994
- 1994-10-28 US US08/331,296 patent/US5514785A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE69032425T2 (de)	1998-11-26
ATE167523T1 (de)	1998-07-15
ES2116977T3 (es)	1998-08-01
EP0455905A2 (de)	1991-11-13
EP0455905A3 (en)	1992-10-07
US5514785A (en)	1996-05-07
EP0455905B1 (de)	1998-06-17
EP0745689A2 (de)	1996-12-04
EP0745689A3 (de)	1996-12-11
DK0455905T3 (da)	1998-12-07
JPH0420300A (ja)	1992-01-23

Legal Events

Date	Code	Title	Description
1999-07-15	8364	No opposition during term of opposition

Publication	Publication Date	Title
ATE167523T1 (de)	1998-07-15	Teststreifen zum eintauchen für nukleinsäure- hybridisierungsassays und verfahren zur kovalenten immobilisierung von oligonucleotiden
DE69509925D1 (de)	1999-07-01	Verfahren und vorrichtung zur herstellung von mikromatrizen für biologische proben
ATE147860T1 (de)	1997-02-15	Verfahren zur immobilisierung von nukleinsäure an einer festen oberfläche zur anwendung in nukleinsäure-hybridizierungstests
DE69535240D1 (de)	2006-11-09	Zusammensetzungen und Verfahren für die gleichzeitige Detektion und Quantifizierung von einer Mehrheit spezifischer Nuklein Säure Sequenzen
DE69434066D1 (de)	2004-11-18	Verfahren zur immobilisierung von nukleinsäure-molekülen
PT975427E (pt)	2001-08-30	Dispositivo que permite um ensaio utilizacao de uma mebrana para fabricar o referido dispositivo e metodo para a deteccao de um analito utilizando tal dispositivo
ATE220341T1 (de)	2002-07-15	Verfahren zur trennung doppelsträngiger dna von einzelsträngiger dna oder rna
ATE138197T1 (de)	1996-06-15	Analyseelement und verfahren zu seiner herstellung
DE69230736D1 (de)	2000-04-06	Verfahren zur Charakterisierung genomischer DNA
CA2250706A1 (en)	1997-11-06	Method and reagent for detecting multiple nucleic acid sequences in a test sample
DE69706187D1 (de)	2001-09-20	Zusammensetzungen und verfahren zur immobilisierung von nukleinsäure auf festträgern
DE69206080D1 (de)	1995-12-21	Element und verfahren für nuklein-säure amplifikation und nachweis unter verwendung von adhärierten sonden.
DE69404657D1 (de)	1997-09-04	Verfahren und vorrichtung zur durchfürung einer vielzahl von chemischen reaktionen auf einer traegerflaeche
ATE91708T1 (de)	1993-08-15	Verfahren zur freisetzung von rns und dns aus zellen.
ATE110851T1 (de)	1994-09-15	Testträger für die analyse einer probenflüssigkeit und verfahren zu seiner herstellung.
ATE54028T1 (de)	1990-07-15	Hybridisierungstest fuer nukleinsaeure mittels anwendung von nachweisbaren antihybridantik¯rpern.
ATE334224T1 (de)	2006-08-15	Nukleinsäure-sonden für chlamydia pneumoniae
CA2282704A1 (en)	1998-09-03	Assaying nucleotides in solution using pna probes
DE69026024D1 (de)	1996-04-25	Künstlicher Träger zur Immobilisierung von biologischen Proteinen und Verfahren zu seiner Herstellung
KR950701339A (ko)	1995-03-23	결핵균에 대한 핵산 반응 프로브(Nucleic Acid Process Probes to Mycobacterium tuberculosis)
DE59307931D1 (de)	1998-02-12	Spezifische Gensonden und Verfahren zur Diagnostik von Candida albicans
ATE284536T1 (de)	2004-12-15	Analytisches messverfahren und seine verwendung
FR2616682B1 (fr)	1989-10-06	Appareil d'agitation selective des teintes de base de peinture, notamment pour carrosseries automobiles
DE59308492D1 (de)	1998-06-10	Fotochemische Markierung von Nukleinsäuren mit Digoxigenin-Reagenzien und ihre Verwendung in Gensondentestsystemen
DE3783399D1 (de)	1993-02-18	Verfahren fuer biologische reaktionen mittels an traegern immobilisierten zellen und vorrichtung zur durchfuehrung des verfahrens.